CA2581150A1 - (spirocyclylamido) aminothiophene compounds as c-kit proto- oncogene inhibitors - Google Patents
(spirocyclylamido) aminothiophene compounds as c-kit proto- oncogene inhibitors Download PDFInfo
- Publication number
- CA2581150A1 CA2581150A1 CA002581150A CA2581150A CA2581150A1 CA 2581150 A1 CA2581150 A1 CA 2581150A1 CA 002581150 A CA002581150 A CA 002581150A CA 2581150 A CA2581150 A CA 2581150A CA 2581150 A1 CA2581150 A1 CA 2581150A1
- Authority
- CA
- Canada
- Prior art keywords
- 6alkyl
- amino
- thiophene
- ylmethyl
- quinolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 title description 19
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 title description 19
- 239000003112 inhibitor Substances 0.000 title description 6
- GLQWRXYOTXRDNH-UHFFFAOYSA-N thiophen-2-amine Chemical class NC1=CC=CS1 GLQWRXYOTXRDNH-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 92
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 150000001204 N-oxides Chemical class 0.000 claims abstract description 37
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims abstract description 14
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims abstract description 14
- 208000000587 small cell lung carcinoma Diseases 0.000 claims abstract description 14
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims abstract description 13
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims abstract description 13
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 12
- 208000000516 mast-cell leukemia Diseases 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 7
- 201000008275 breast carcinoma Diseases 0.000 claims abstract description 7
- 208000008585 mastocytosis Diseases 0.000 claims abstract description 7
- 201000001441 melanoma Diseases 0.000 claims abstract description 7
- 201000003076 Angiosarcoma Diseases 0.000 claims abstract description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims abstract description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims abstract description 6
- 208000001258 Hemangiosarcoma Diseases 0.000 claims abstract description 6
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 6
- 201000010208 Seminoma Diseases 0.000 claims abstract description 6
- 206010042971 T-cell lymphoma Diseases 0.000 claims abstract description 6
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims abstract description 6
- 208000024313 Testicular Neoplasms Diseases 0.000 claims abstract description 6
- 206010057644 Testis cancer Diseases 0.000 claims abstract description 6
- 208000033781 Thyroid carcinoma Diseases 0.000 claims abstract description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims abstract description 6
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims abstract description 6
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims abstract description 6
- 201000003914 endometrial carcinoma Diseases 0.000 claims abstract description 6
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 6
- 201000001514 prostate carcinoma Diseases 0.000 claims abstract description 6
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims abstract description 6
- 201000003120 testicular cancer Diseases 0.000 claims abstract description 6
- 201000002510 thyroid cancer Diseases 0.000 claims abstract description 6
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims abstract description 6
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims abstract description 5
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims abstract description 5
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims abstract description 5
- 206010029260 Neuroblastoma Diseases 0.000 claims abstract description 5
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims abstract description 4
- -1 cycloC3-10alkyl Chemical group 0.000 claims description 114
- 238000000034 method Methods 0.000 claims description 62
- 239000000203 mixture Substances 0.000 claims description 61
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 51
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 claims description 48
- 125000001424 substituent group Chemical group 0.000 claims description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 125000002252 acyl group Chemical group 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 230000003463 hyperproliferative effect Effects 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 239000012830 cancer therapeutic Substances 0.000 claims description 4
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 claims description 4
- CPESOWHXWLASTP-UHFFFAOYSA-N 4-methyl-n-(2'-oxospiro[1,3-dioxolane-2,3'-1h-indole]-5'-yl)-3-(quinolin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound C=1C=NC2=CC=CC=C2C=1CNC=1C(C)=CSC=1C(=O)NC(C=C12)=CC=C1NC(=O)C12OCCO1 CPESOWHXWLASTP-UHFFFAOYSA-N 0.000 claims description 3
- 125000004442 acylamino group Chemical group 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 3
- 230000000259 anti-tumor effect Effects 0.000 claims description 3
- 229940034982 antineoplastic agent Drugs 0.000 claims description 3
- IPRBKPGIQVANDZ-UHFFFAOYSA-N benzyl 2-oxo-5-[[3-(quinolin-4-ylmethylamino)thiophene-2-carbonyl]amino]spiro[1h-indole-3,4'-piperidine]-1'-carboxylate Chemical compound S1C=CC(NCC=2C3=CC=CC=C3N=CC=2)=C1C(=O)NC(C=C12)=CC=C1NC(=O)C2(CC1)CCN1C(=O)OCC1=CC=CC=C1 IPRBKPGIQVANDZ-UHFFFAOYSA-N 0.000 claims description 3
- JSGFDCYBZHOBIT-UHFFFAOYSA-N n-(1',3'-dimethyl-2-oxospiro[1h-indole-3,2'-imidazolidine]-5-yl)-3-(quinolin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound CN1CCN(C)C11C2=CC(NC(=O)C3=C(C=CS3)NCC=3C4=CC=CC=C4N=CC=3)=CC=C2NC1=O JSGFDCYBZHOBIT-UHFFFAOYSA-N 0.000 claims description 3
- MVMAADCFZGKMSE-UHFFFAOYSA-N n-(2'-oxospiro[1,3-dioxane-2,3'-1h-indole]-5'-yl)-3-(quinolin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound S1C=CC(NCC=2C3=CC=CC=C3N=CC=2)=C1C(=O)NC(C=C12)=CC=C1NC(=O)C12OCCCO1 MVMAADCFZGKMSE-UHFFFAOYSA-N 0.000 claims description 3
- CPCYGYYVPDNARJ-UHFFFAOYSA-N n-(2-methyl-3-oxo-1,2-diazaspiro[4.5]decan-8-yl)-3-(quinolin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound C1C(=O)N(C)NC21CCC(NC(=O)C1=C(C=CS1)NCC=1C3=CC=CC=C3N=CC=1)CC2 CPCYGYYVPDNARJ-UHFFFAOYSA-N 0.000 claims description 3
- XXHAPVLOWYPEEX-UHFFFAOYSA-N n-(3-methyl-2,4-dioxo-1,3-diazaspiro[4.5]decan-8-yl)-3-(quinolin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound O=C1N(C)C(=O)NC11CCC(NC(=O)C2=C(C=CS2)NCC=2C3=CC=CC=C3N=CC=2)CC1 XXHAPVLOWYPEEX-UHFFFAOYSA-N 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- GWWHXHANUWZCAG-UHFFFAOYSA-N 3-(pyridin-4-ylmethylamino)-n-spiro[1,2-dihydroindole-3,2'-1,3-dioxolane]-5-ylthiophene-2-carboxamide Chemical compound S1C=CC(NCC=2C=CN=CC=2)=C1C(=O)NC(C=C12)=CC=C1NCC12OCCO1 GWWHXHANUWZCAG-UHFFFAOYSA-N 0.000 claims description 2
- OPBXXXPTORNWDS-UHFFFAOYSA-N 4-methyl-n-(2'-oxospiro[1,3-dithiolane-2,3'-1h-indole]-5'-yl)-3-(quinolin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound C=1C=NC2=CC=CC=C2C=1CNC=1C(C)=CSC=1C(=O)NC(C=C12)=CC=C1NC(=O)C12SCCS1 OPBXXXPTORNWDS-UHFFFAOYSA-N 0.000 claims description 2
- UWJUOZLCUPDENZ-UHFFFAOYSA-N 4-methyl-n-[3-(3-methylbutyl)-2,4-dioxo-1,3-diazaspiro[4.5]decan-8-yl]-3-(quinolin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound O=C1N(CCC(C)C)C(=O)NC11CCC(NC(=O)C2=C(C(C)=CS2)NCC=2C3=CC=CC=C3N=CC=2)CC1 UWJUOZLCUPDENZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
- XFPLEYSSZRHJJD-UHFFFAOYSA-N n-(1',3'-dimethyl-2-oxospiro[1h-indole-3,2'-imidazolidine]-5-yl)-4-methyl-3-(quinolin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound CN1CCN(C)C11C2=CC(NC(=O)C3=C(C(C)=CS3)NCC=3C4=CC=CC=C4N=CC=3)=CC=C2NC1=O XFPLEYSSZRHJJD-UHFFFAOYSA-N 0.000 claims description 2
- MZYDRIRNAYARAR-UHFFFAOYSA-N n-(1,4-dioxaspiro[4.5]decan-8-yl)-4-methyl-3-(quinolin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound C=1C=NC2=CC=CC=C2C=1CNC=1C(C)=CSC=1C(=O)NC(CC1)CCC21OCCO2 MZYDRIRNAYARAR-UHFFFAOYSA-N 0.000 claims description 2
- JYONHFRWOMXWLM-UHFFFAOYSA-N n-(2'-oxospiro[1,3-dioxolane-2,3'-1h-indole]-5'-yl)-3-(quinolin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound S1C=CC(NCC=2C3=CC=CC=C3N=CC=2)=C1C(=O)NC(C=C12)=CC=C1NC(=O)C12OCCO1 JYONHFRWOMXWLM-UHFFFAOYSA-N 0.000 claims description 2
- XQCMHOHMFYJTBN-UHFFFAOYSA-N n-(2'-oxospiro[1,3-dithiolane-2,3'-1h-indole]-5'-yl)-3-(quinolin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound S1C=CC(NCC=2C3=CC=CC=C3N=CC=2)=C1C(=O)NC(C=C12)=CC=C1NC(=O)C12SCCS1 XQCMHOHMFYJTBN-UHFFFAOYSA-N 0.000 claims description 2
- VHTGPNJGKQIUJZ-UHFFFAOYSA-N n-(3-benzyl-2,4-dioxo-1,3-diazaspiro[4.5]decan-8-yl)-3-(quinolin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound S1C=CC(NCC=2C3=CC=CC=C3N=CC=2)=C1C(=O)NC(CC1)CCC1(C1=O)NC(=O)N1CC1=CC=CC=C1 VHTGPNJGKQIUJZ-UHFFFAOYSA-N 0.000 claims description 2
- RLMXAUOEATVEIP-UHFFFAOYSA-N n-(3-oxo-2-azaspiro[4.5]decan-8-yl)-3-(quinolin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound S1C=CC(NCC=2C3=CC=CC=C3N=CC=2)=C1C(=O)NC(CC1)CCC21CNC(=O)C2 RLMXAUOEATVEIP-UHFFFAOYSA-N 0.000 claims description 2
- XZVSBZXNIVRESN-UHFFFAOYSA-N n-[3-(3-methylbutyl)-2,4-dioxo-1,3-diazaspiro[4.5]decan-8-yl]-3-(quinolin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound O=C1N(CCC(C)C)C(=O)NC11CCC(NC(=O)C2=C(C=CS2)NCC=2C3=CC=CC=C3N=CC=2)CC1 XZVSBZXNIVRESN-UHFFFAOYSA-N 0.000 claims description 2
- YNSCKPCDFIDINW-UHFFFAOYSA-N 3-[[2-[[1-[2-(dimethylamino)acetyl]-6-methoxy-4,4-dimethyl-2,3-dihydroquinolin-7-yl]amino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]amino]thiophene-2-carboxamide Chemical compound COC1=CC(C(CCN2C(=O)CN(C)C)(C)C)=C2C=C1NC(N=C1NC=CC1=1)=NC=1NC=1C=CSC=1C(N)=O YNSCKPCDFIDINW-UHFFFAOYSA-N 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 74
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 62
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 52
- 239000000243 solution Substances 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 229910001868 water Inorganic materials 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 19
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 101150041968 CDC13 gene Proteins 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 239000000725 suspension Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- KDAFVGCPLFJMHY-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-amine Chemical compound C1CC(N)CCC21OCCO2 KDAFVGCPLFJMHY-UHFFFAOYSA-N 0.000 description 11
- OOGZQDAEOJYGAL-UHFFFAOYSA-N 3-(quinolin-4-ylmethylamino)thiophene-2-carboxylic acid;hydrochloride Chemical compound Cl.S1C=CC(NCC=2C3=CC=CC=C3N=CC=2)=C1C(=O)O OOGZQDAEOJYGAL-UHFFFAOYSA-N 0.000 description 11
- 108091000080 Phosphotransferase Proteins 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 239000012298 atmosphere Substances 0.000 description 11
- 102000020233 phosphotransferase Human genes 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 102100020880 Kit ligand Human genes 0.000 description 8
- 108010039445 Stem Cell Factor Proteins 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- MVYSLZVXHMBEQS-UHFFFAOYSA-N methyl 3-(quinolin-4-ylmethylamino)thiophene-2-carboxylate Chemical compound S1C=CC(NCC=2C3=CC=CC=C3N=CC=2)=C1C(=O)OC MVYSLZVXHMBEQS-UHFFFAOYSA-N 0.000 description 8
- TWEQNZZOOFKOER-UHFFFAOYSA-N methyl 3-aminothiophene-2-carboxylate Chemical compound COC(=O)C=1SC=CC=1N TWEQNZZOOFKOER-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- JNPBKQOVSMBPGE-UHFFFAOYSA-N benzyl n-(4-hydroxycyclohexyl)carbamate Chemical compound C1CC(O)CCC1NC(=O)OCC1=CC=CC=C1 JNPBKQOVSMBPGE-UHFFFAOYSA-N 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000012911 assay medium Substances 0.000 description 6
- VHXBIBFCJISKFA-UHFFFAOYSA-N benzyl n-(4-oxocyclohexyl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1CCC(=O)CC1 VHXBIBFCJISKFA-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 6
- JVHUINBMBKRXSW-UHFFFAOYSA-N 9-amino-1,4-dimethyl-1,4-diazaspiro[5.5]undecan-5-one Chemical compound O=C1N(C)CCN(C)C11CCC(N)CC1 JVHUINBMBKRXSW-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
- GXGWZEFTMBLEBW-UHFFFAOYSA-N benzyl 5-nitrospiro[1,2-dihydroindole-3,4'-piperidine]-1'-carboxylate Chemical compound C12=CC([N+](=O)[O-])=CC=C2NCC1(CC1)CCN1C(=O)OCC1=CC=CC=C1 GXGWZEFTMBLEBW-UHFFFAOYSA-N 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- YICRPERKKBDRSP-UHFFFAOYSA-N methyl 3-amino-4-methylthiophene-2-carboxylate Chemical compound COC(=O)C=1SC=C(C)C=1N YICRPERKKBDRSP-UHFFFAOYSA-N 0.000 description 5
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- GKZFFHBXAICCGE-UHFFFAOYSA-N spiro[1,2-dihydroindole-3,2'-1,3-dioxolane]-5-amine Chemical compound C12=CC(N)=CC=C2NCC21OCCO2 GKZFFHBXAICCGE-UHFFFAOYSA-N 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- KWHMJJGEPIFDHX-UHFFFAOYSA-N tert-butyl n-(1'-methyl-2-oxospiro[1h-indole-3,4'-piperidine]-5-yl)carbamate Chemical compound C1CN(C)CCC21C1=CC(NC(=O)OC(C)(C)C)=CC=C1NC2=O KWHMJJGEPIFDHX-UHFFFAOYSA-N 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- JQKZSACVBHBOLG-UHFFFAOYSA-N 5'-aminospiro[1,3-dioxolane-2,3'-1h-indole]-2'-one Chemical compound C12=CC(N)=CC=C2NC(=O)C21OCCO2 JQKZSACVBHBOLG-UHFFFAOYSA-N 0.000 description 4
- GTHAWHPVPJKKQN-UHFFFAOYSA-N 5-amino-1'-methylspiro[1h-indole-3,4'-piperidine]-2-one Chemical compound C1CN(C)CCC21C1=CC(N)=CC=C1NC2=O GTHAWHPVPJKKQN-UHFFFAOYSA-N 0.000 description 4
- BVLKRYJHZIYNIK-UHFFFAOYSA-N 8-amino-2-azaspiro[4.5]decan-3-one Chemical compound C1CC(N)CCC11CC(=O)NC1 BVLKRYJHZIYNIK-UHFFFAOYSA-N 0.000 description 4
- VOZFUOMXANMOMO-UHFFFAOYSA-N 8-amino-2-methyl-1,2-diazaspiro[4.5]decan-3-one Chemical compound C1C(=O)N(C)NC21CCC(N)CC2 VOZFUOMXANMOMO-UHFFFAOYSA-N 0.000 description 4
- MNZBRQWKTCHVPT-UHFFFAOYSA-N 8-amino-3-benzyl-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound C1CC(N)CCC21C(=O)N(CC=1C=CC=CC=1)C(=O)N2 MNZBRQWKTCHVPT-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- RYZULZSNTCNSBG-UHFFFAOYSA-N methyl 2-[4-(phenylmethoxycarbonylamino)cyclohexylidene]acetate Chemical compound C1CC(=CC(=O)OC)CCC1NC(=O)OCC1=CC=CC=C1 RYZULZSNTCNSBG-UHFFFAOYSA-N 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- JSCSVSIJJQSNPH-UHFFFAOYSA-N tert-butyl n-(2-oxo-1,3-dihydroindol-5-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C2NC(=O)CC2=C1 JSCSVSIJJQSNPH-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 3
- ZOVHMRBVMUOGSF-UHFFFAOYSA-N 5'-nitrospiro[1,3-dioxolane-2,3'-1h-indole]-2'-one Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)C21OCCO2 ZOVHMRBVMUOGSF-UHFFFAOYSA-N 0.000 description 3
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 108091005682 Receptor kinases Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- DMDXYVKVLKYIIV-UHFFFAOYSA-N benzyl 5-aminospiro[1,2-dihydroindole-3,4'-piperidine]-1'-carboxylate Chemical compound C12=CC(N)=CC=C2NCC1(CC1)CCN1C(=O)OCC1=CC=CC=C1 DMDXYVKVLKYIIV-UHFFFAOYSA-N 0.000 description 3
- VXPGIKZPRNJDFJ-UHFFFAOYSA-N benzyl n-(3-benzyl-2,4-dioxo-1,3-diazaspiro[4.5]decan-8-yl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(CC1)CCC1(C1=O)NC(=O)N1CC1=CC=CC=C1 VXPGIKZPRNJDFJ-UHFFFAOYSA-N 0.000 description 3
- IYOXHBPCRVHVST-UHFFFAOYSA-N benzyl n-(3-oxo-2-azaspiro[4.5]decan-8-yl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(CC1)CCC21CNC(=O)C2 IYOXHBPCRVHVST-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- OQEVGOXHAPOMDT-UHFFFAOYSA-N methyl 2-[1-(nitromethyl)-4-(phenylmethoxycarbonylamino)cyclohexyl]acetate Chemical compound C1CC(CC(=O)OC)(C[N+]([O-])=O)CCC1NC(=O)OCC1=CC=CC=C1 OQEVGOXHAPOMDT-UHFFFAOYSA-N 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- JPTDPTOWOMFBRY-UHFFFAOYSA-N 1-methyl-5-nitroindole-2,3-dione Chemical compound [O-][N+](=O)C1=CC=C2N(C)C(=O)C(=O)C2=C1 JPTDPTOWOMFBRY-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- RDKQQYIIGDTKTG-UHFFFAOYSA-N 3-(quinolin-4-ylmethylamino)-n-(1,1',3-trimethyl-2'-oxospiro[imidazolidine-2,3'-indole]-5'-yl)thiophene-2-carboxamide Chemical compound CN1CCN(C)C11C2=CC(NC(=O)C3=C(C=CS3)NCC=3C4=CC=CC=C4N=CC=3)=CC=C2N(C)C1=O RDKQQYIIGDTKTG-UHFFFAOYSA-N 0.000 description 2
- UNMYHYODJHKLOC-UHFFFAOYSA-N 5-Nitroisatin Chemical compound [O-][N+](=O)C1=CC=C2NC(=O)C(=O)C2=C1 UNMYHYODJHKLOC-UHFFFAOYSA-N 0.000 description 2
- BRPUIGNBCAZPLL-UHFFFAOYSA-N 8-amino-2-benzyl-1,2-diazaspiro[4.5]decan-3-one Chemical compound C1CC(N)CCC11NN(CC=2C=CC=CC=2)C(=O)C1 BRPUIGNBCAZPLL-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- QAUGFEOPDVJKDF-UHFFFAOYSA-N benzyl n-(1,4-dimethyl-5-oxo-1,4-diazaspiro[5.5]undecan-9-yl)carbamate Chemical compound O=C1N(C)CCN(C)C11CCC(NC(=O)OCC=2C=CC=CC=2)CC1 QAUGFEOPDVJKDF-UHFFFAOYSA-N 0.000 description 2
- JHMVEEKLKZGHJR-UHFFFAOYSA-N benzyl n-(1,4-dioxaspiro[4.5]decan-8-yl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(CC1)CCC21OCCO2 JHMVEEKLKZGHJR-UHFFFAOYSA-N 0.000 description 2
- IJZCBKSDHPKEMJ-UHFFFAOYSA-N benzyl n-(2-methyl-3-oxo-1,2-diazaspiro[4.5]decan-8-yl)carbamate Chemical compound C1C(=O)N(C)NC21CCC(NC(=O)OCC=1C=CC=CC=1)CC2 IJZCBKSDHPKEMJ-UHFFFAOYSA-N 0.000 description 2
- NHOWLEZFTHYCTP-UHFFFAOYSA-N benzylhydrazine Chemical compound NNCC1=CC=CC=C1 NHOWLEZFTHYCTP-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000008004 cell lysis buffer Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- SVJAKSYVLOSOII-UHFFFAOYSA-N n-(1'-methyl-2-oxospiro[1h-indole-3,4'-piperidine]-5-yl)-3-(quinolin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound C1CN(C)CCC21C1=CC(NC(=O)C3=C(C=CS3)NCC=3C4=CC=CC=C4N=CC=3)=CC=C1NC2=O SVJAKSYVLOSOII-UHFFFAOYSA-N 0.000 description 2
- TWWNEVYYPUABJV-UHFFFAOYSA-N n-(1,4-dioxaspiro[4.5]decan-8-yl)-3-(quinolin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound S1C=CC(NCC=2C3=CC=CC=C3N=CC=2)=C1C(=O)NC(CC1)CCC21OCCO2 TWWNEVYYPUABJV-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- WPYJKGWLDJECQD-UHFFFAOYSA-N quinoline-2-carbaldehyde Chemical compound C1=CC=CC2=NC(C=O)=CC=C21 WPYJKGWLDJECQD-UHFFFAOYSA-N 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 238000009094 second-line therapy Methods 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000003577 thiophenes Chemical class 0.000 description 2
- 238000009095 third-line therapy Methods 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 125000005023 xylyl group Chemical group 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- VYVPNTJBGPQTFA-UHFFFAOYSA-N 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCOCCOS(=O)(=O)C1=CC=C(C)C=C1 VYVPNTJBGPQTFA-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- RKTQEVMZBCBOSB-UHFFFAOYSA-N 4-aminocyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1CCC(O)CC1 RKTQEVMZBCBOSB-UHFFFAOYSA-N 0.000 description 1
- UQRONKZLYKUEMO-UHFFFAOYSA-N 4-methyl-1-(2,4,6-trimethylphenyl)pent-4-en-2-one Chemical group CC(=C)CC(=O)Cc1c(C)cc(C)cc1C UQRONKZLYKUEMO-UHFFFAOYSA-N 0.000 description 1
- RJWLLQWLBMJCFD-UHFFFAOYSA-N 4-methylpiperazin-1-amine Chemical compound CN1CCN(N)CC1 RJWLLQWLBMJCFD-UHFFFAOYSA-N 0.000 description 1
- KMVPXBDOWDXXEN-UHFFFAOYSA-N 4-nitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1 KMVPXBDOWDXXEN-UHFFFAOYSA-N 0.000 description 1
- JPUYXUBUJJDJNL-UHFFFAOYSA-N 5-amino-1,3-dihydroindol-2-one Chemical compound NC1=CC=C2NC(=O)CC2=C1 JPUYXUBUJJDJNL-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- JCXDTIUHHJYRBR-UHFFFAOYSA-N 8-amino-3-(3-methylbutyl)-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCC(C)C)C(=O)NC11CCC(N)CC1 JCXDTIUHHJYRBR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 102100022210 COX assembly mitochondrial protein 2 homolog Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000900446 Homo sapiens COX assembly mitochondrial protein 2 homolog Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910017974 NH40H Inorganic materials 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 229910008066 SnC12 Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 229940116211 Vasopressin antagonist Drugs 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- RBVJYBZVYOGEOK-UHFFFAOYSA-N [2-[(2,2-dimethylhydrazinyl)-[2-(methylamino)hydrazinyl]amino]hydrazinyl]ethane Chemical compound CCNNN(NN(C)C)NNNC RBVJYBZVYOGEOK-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- ZJQMLJFHCKTCSF-UHFFFAOYSA-N benzyl 4-formylpiperidine-1-carboxylate Chemical compound C1CC(C=O)CCN1C(=O)OCC1=CC=CC=C1 ZJQMLJFHCKTCSF-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- VRIGXRJROUDGHA-UHFFFAOYSA-N benzyl n-(2,4-dioxo-1,3-diazaspiro[4.5]decan-8-yl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(CC1)CCC21NC(=O)NC2=O VRIGXRJROUDGHA-UHFFFAOYSA-N 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000002592 cumenyl group Chemical group C1(=C(C=CC=C1)*)C(C)C 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- NTNUDYROPUKXNA-UHFFFAOYSA-N methyl 2-(triphenyl-$l^{5}-phosphanylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OC)C1=CC=CC=C1 NTNUDYROPUKXNA-UHFFFAOYSA-N 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- KFIGICHILYTCJF-UHFFFAOYSA-N n'-methylethane-1,2-diamine Chemical compound CNCCN KFIGICHILYTCJF-UHFFFAOYSA-N 0.000 description 1
- QGBRIMREFJGOOT-UHFFFAOYSA-N n-(2,4-dioxo-1,3-diazaspiro[4.5]decan-8-yl)-3-(quinolin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound S1C=CC(NCC=2C3=CC=CC=C3N=CC=2)=C1C(=O)NC(CC1)CCC21NC(=O)NC2=O QGBRIMREFJGOOT-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000005009 perfluoropropyl group Chemical group FC(C(C(F)(F)F)(F)F)(F)* 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000014483 powder concentrate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 150000003413 spiro compounds Chemical class 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001166 thiolanyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 239000003038 vasopressin antagonist Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, R1, X and Y are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis/mast cell leukemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma.
Description
TITLE OF THE INVENTION
(SPIROCYCLYLAMIDO)AMINOTHIOPHENE COMPOUNDS AS C-KIT PROTO-ONCOGENE INHIBITORS
BACKGROUND OF THE INVENTION
[1] The present invention is directed to disubstituted thiophenes. In particular, the present invention is directed to (spirocyclylamido)(amino)thiophenes that are inhibitors of c-Kit proto-oncogene (also known as Kit, CD-117, stem cell factor receptor, mast cell growth factor receptor).
(SPIROCYCLYLAMIDO)AMINOTHIOPHENE COMPOUNDS AS C-KIT PROTO-ONCOGENE INHIBITORS
BACKGROUND OF THE INVENTION
[1] The present invention is directed to disubstituted thiophenes. In particular, the present invention is directed to (spirocyclylamido)(amino)thiophenes that are inhibitors of c-Kit proto-oncogene (also known as Kit, CD-117, stem cell factor receptor, mast cell growth factor receptor).
[2] The c-Kit proto-oncogene is believed to be important in embryogenesis, melanogenesis, hematopoiesis, and the pathogenesis of mastocytosis, gastrointestinal tumors, and other solid tumors, as well as certain leukemias, including AML.
Accordingly, it would be desirable to develop novel compounds that are inhibitors of the c-Kit receptor.
Accordingly, it would be desirable to develop novel compounds that are inhibitors of the c-Kit receptor.
[3] Many of the current treatment regimes for hyperproliferative disorders (cancer) utilize compounds that inhibit DNA synthesis. Such compounds' mechanism of operation is to be toxic to cells, particularly to rapidly dividing tumor cells. Thus, their broad toxicity can be a problem to the subject patient. However, other approaches to anti-cancer agents that act other than by the inhibition of DNA synthesis have been explored to try to enhance the selectivity of the anti-cancer action and thereby reduce adverse side-effects.
[4] It is lmown that a cell may become cancerous by virtue of the transformation of a portion of its DNA into an oncogene (i.e. a gene which, on activation, leads to the formation of malignant tumor cells). Many oncogenes encode proteins that are aberrant protein-tyrosine kinases capable of causing cell transformation. By a different route, the overexpression of a normal proto-oncogenic tyrosine kinase can also result in proliferative disorders, sometimes resulting in a malignant phenotype. Alternatively, co-expression of a receptor tyrosine kinase and its cognate ligand within the same cell type may also lead to malignant transformation.
[5] Receptor tyrosine kinases are large enzymes which span the cell membrane and possess i) an extracellular binding domain for growth factors such as KIT
ligand (also lazown as stem cell factor (SCF), Steel factor (SLF) or mast cell growth factor (MGF)), ii) a transmembrane domain, and iii) an intracellular portion which functions as a kinase to phosphorylate specific tyrosine residues in proteins. Binding of KIT ligand to KIT tyrosine lcinase results in receptor homodimerization, the activation of KIT tyrosine kinase activity, and the subsequent phosphorylation of a variety of protein substrates, many of which are effectors of intracellular signal transduction, These events can lead to enhanced cell proliferation or promote enhanced cell survival. With some receptor kinases, receptor heterodimerization can also occur.
ligand (also lazown as stem cell factor (SCF), Steel factor (SLF) or mast cell growth factor (MGF)), ii) a transmembrane domain, and iii) an intracellular portion which functions as a kinase to phosphorylate specific tyrosine residues in proteins. Binding of KIT ligand to KIT tyrosine lcinase results in receptor homodimerization, the activation of KIT tyrosine kinase activity, and the subsequent phosphorylation of a variety of protein substrates, many of which are effectors of intracellular signal transduction, These events can lead to enhanced cell proliferation or promote enhanced cell survival. With some receptor kinases, receptor heterodimerization can also occur.
[6] It is known that such kinases are frequently aberrantly expressed in common human cancers such as breast cancer, head and neck cancers, gastrointestinal cancer such as colon, rectal or stomach cancer, leukemia, and ovarian, bronchial, lung or pancreatic cancer.
Kit kinase expression has been documented in a wide variety of human malignancies such as mastocytosis/mast cell leukemia, gastrointestinal stromal tumors (GIST), small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leulcemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma. The kinase activity of KIT has been implicated in the pathophysiology of several of these - and additional tumors - including breast carcinoma, SCLC, GIST, germ cell tumors, mast cell leukemia, neuroblastoma, AML, melanoma and ovarian carcinoma.
Kit kinase expression has been documented in a wide variety of human malignancies such as mastocytosis/mast cell leukemia, gastrointestinal stromal tumors (GIST), small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leulcemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma. The kinase activity of KIT has been implicated in the pathophysiology of several of these - and additional tumors - including breast carcinoma, SCLC, GIST, germ cell tumors, mast cell leukemia, neuroblastoma, AML, melanoma and ovarian carcinoma.
[7] Several mechanisms of KIT activation in tumor cells have been reported, including activating mutations, autocrine and paracrine activation of the receptor kinase by its ligand, loss of protein-tyrosine phosphatase activity, and cross activation by other kinases.
The transforming mechanisms initiated by the activating mutations are thought to include dimer formation and increased intrinsic activity of the kinase domain, both of which result in constitutive ligand-independent kinase activation, and possibly altered substrate specificity.
More than thirty activating mutations of the Kit protein have been associated with highly malignant tumors in humans.
The transforming mechanisms initiated by the activating mutations are thought to include dimer formation and increased intrinsic activity of the kinase domain, both of which result in constitutive ligand-independent kinase activation, and possibly altered substrate specificity.
More than thirty activating mutations of the Kit protein have been associated with highly malignant tumors in humans.
[8] Accordingly, it has been recognized that inhibitors of receptor tyrosine kinases are useful as selective inhibitors of the growth of mammalian cancer cells. For example, GleevecTM (also lcnown as imatinib mesylate, or STI571), a 2-phenylpyrimidine tyrosine kinase inhibitor that inhibits the kinase activity of the BCR-ABL
fusion gene product, was recently approved by the U.S. Food and Drug Administration for the treatment of CML. GleevecTM, in addition to inhibiting BCR-ABL kinase, also inhibits the KIT lcinase and PDGF receptor kinase, although it is not effective against all mutant isoforms of the KIT
kinase. Kit ligand-stimulated growth of M07e human leukemia cells is inhibited by GleevecTM, which also induces apoptosis under these conditions. By contrast, GM-CSF
stimulated growth of M07e human leukemia cells is not affected by GleevecTM.
Further, in recent clinical studies using GleevecTM to treat patients with GIST, a disease in which KIT
lcinase is involved in transformation of the cells, many of the patients showed marked improvement.
fusion gene product, was recently approved by the U.S. Food and Drug Administration for the treatment of CML. GleevecTM, in addition to inhibiting BCR-ABL kinase, also inhibits the KIT lcinase and PDGF receptor kinase, although it is not effective against all mutant isoforms of the KIT
kinase. Kit ligand-stimulated growth of M07e human leukemia cells is inhibited by GleevecTM, which also induces apoptosis under these conditions. By contrast, GM-CSF
stimulated growth of M07e human leukemia cells is not affected by GleevecTM.
Further, in recent clinical studies using GleevecTM to treat patients with GIST, a disease in which KIT
lcinase is involved in transformation of the cells, many of the patients showed marked improvement.
[9] These studies demonstrate how KIT kinase inhibitors can treat tumors whose growth is dependent on KIT kinase activity. Other kinase inhibitors show even greater kinase selectivity. For example, the 4-anilinoquinazoline compound TarcevaTM inhibits only EGF
receptor lcinase with high potency, although it can inhibit the signal transduction of other receptor kinases, probably by virtue of the fact that these receptors heterodimerize with EGF
receptor.
receptor lcinase with high potency, although it can inhibit the signal transduction of other receptor kinases, probably by virtue of the fact that these receptors heterodimerize with EGF
receptor.
[10] Although anti-cancer compounds such as those described above make a significant contribution to the art, there is a continuing need for improved anti-cancer pharmaceuticals, and it would be desirable to develop new compounds with better selectivity or potency, or with reduced toxicity or side effects.
[11] International Patent Publication No. W002/00651 describes factor Xa inhibitors. U.S. Patent No. 6,054,457 describes benzamide derivatives and their use as vasopressin antagonists.
SUMMARY OF THE INVENTION
SUMMARY OF THE INVENTION
[12] Compounds represented by Formula (I):
Y
S N
I H
RI
NH
A
Y
S N
I H
RI
NH
A
[13] or a pharmaceutically acceptable salt or N-oxide thereof. The compounds of Formula (I) are useful in the treatment of tumors and cancers such as mastocytosis/mast cell leulcemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lyinphoma, endometrial carcinoma, and prostate carcinoma.
DETAILED DESCRIPTION OF THE INVENTION
DETAILED DESCRIPTION OF THE INVENTION
[14] The present invention is directed to a compound represented by Formula (I):
O C
S N Y
I H
A
[15] or a pharmaceutically acceptable salt or N-oxide thereof, wherein:
S N Y
I H
A
[15] or a pharmaceutically acceptable salt or N-oxide thereof, wherein:
[16] Y is heteroaryl or cycloC3_loalkyl, either of which is optionally substituted by 1-5 independent Rz substituents;
[17] X is heteroaryl or heterocylyl, either of which is optionally substituted by 1-5 independent R21 substituents;
[18] A is aryl, heteroaryl, cycloC3_loalkyl, heterocyclyl, cycloC3_loalkenyl, or heterocycloalkenyl, each of which is optionally substituted by 1-5 independent substituents;
[19] Rl is Co_6alkyl, halogen, or haloalkyl;
[20] R2, R21, and R3 each independently is Co_6alkyl, cycloC3_1oalkyl, oxo, halogen, haloalkyl, cyanoCO_6alkyl, nitroCO_6alkyl, hydroxyCO_6alkyl, -Co_6alkyl-N(Co_6alkyl)(C0_6alkyl), -N(C0_6alkyl)-N(C0_6alkyl)(Co_6alkyl), -N(Co_6alkyl)-N(Co_6alkyl)(acyl), acylCo_6alkyl, substituted acyl, guanidinoCO_6alkyl, hydroxyiminoCO_6alkyl, acylaminoCo_6alkyl, substituted acylamino, acyloxyCO_6alkyl, substituted acyloxy, arCO_6alkyl, substituted arCo_6alkyl, heteroarylCO_6alkyl, substituted heteroarylCO_6allcyl, heterocyclylCO_6alkyl, cyanoaminoCo_ 6allcyl, C0_6alkylhydrazino, heterocyclylamino, arCO_6alkylhydrazino, alkylsulfonylCo_6alkyl, arCO_6a1ky1sulfonylCo_6alkyl, alkylsulfinylCo_6alkyl, alkylsulfonamidoCO_6alkyl, arCo_ 6a1ky1sulfonamidoCO_6alkyl, aminoCO_6alkylsulfonyl, C0_6alkylaminosulfonyl, acy1C1_ 6alkylsulfonyl, heterocyclylsulfonyl, aminoCO_6alkylsulfinyl, acy1C1_6alkylsulfinyl, silyl, siloxy, alkenoxy, alkynoxy, C2_6alkenyl, acylC2_6alkenyl, C2_6alkynyl, acy1C2_6alkynyl, hydroxyC2_6alkynyl, aminoC2_6alkynyl, Cl_6alkoxyCO_6alkyl, C1_6a1ky1thioCO_6allcyl, hydroxyCl_ 6alkoxyCo_6alkyl, hydroxyCl_6a1ky1thioCO_6alkyl, acy1C1_6alkoxyCO_6alkyl, acy1C1_6a1ky1thioCo_ 6alkyl, Co_6alkylaminoC1_6alkoxyCO_6alkyl, Co_6allcylaminoC1_6a1ky1thioCO_6alkyl, acylaminoCl_ 6a11coxyCO_6alkyl, acylaminoC1_6a1ky1thioCO_6alkyl, arCO_6alkylaminoCo_6alkyl, arCo_ 6a11cylthioCO_6alkyl, arCO_6alkoxyCO_6alkyl, arCo_6alkylamino, arCO_6alkylaminoCO_6alkyl, arCo_ 6alkylthio, substituted arCO_6alkoxy, substituted arCo_6alkylthio,or substituted arCO_6alkoxy;
[21] provided that the compound is not cis-N-(4-methyl-5 -oxo-1,4-diazaspiro [5 .5]undec-9-yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide, cis-N-(2-benzyl-3 -oxo-1,2-diazaspiro[4.5]dec-8-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide, N-(3-benzyl-2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide, cis-N-(2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide, N- [3 -(3 -methylbutyl)-2, 4-dioxo-1, 3 -di azaspiro [4.5 ] dec-8 -yl] -4-methyl-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide, or benzyl5- {[(3-[(quinolin-4-ylmethyl)amino]thien-2-yl)carbonyl]amino} -2-oxo-1,2-dihydro-1'H-spiro [indole-3,4'-piperidine]-1'-carboxylate.
[22] In one aspect, the present invention is directed to a compound represented by Formula (I), or a pharmaceutically acceptable salt or N-oxide thereof, wherein Y is cycloC3_ loalkyl optionally substituted by 1-5 independent R2 substituents; X is heterocyclyl or heteroaryl optionally substituted by 1-5 independent R21 substituents; and the other variables are as described above for Formula (I).
[23] In an embodiment of this one aspect, the present invention is directed to a compound represented by Formula (I), or a pharmaceutically acceptable salt or N-oxide thereof, wherein Y is cyclohexyl optionally substituted by 1-5 independent RZ
substituents; X
is heterocyclyl or heteroaryl; and the other variables are as described above for Formula (I).
substituents; X
is heterocyclyl or heteroaryl; and the other variables are as described above for Formula (I).
[24] In another embodiment of this one aspect, the present invention is directed to a compound represented by Formula (I), or a pharmaceutically acceptable salt or N-oxide thereof, wherein Y is cyclohexyl optionally substituted by 1-5 independent RZ
substituents; X
is heterocyclyl or heteroaryl optionally substituted by 1-5 independent RZ' substituents; A is heteroaryl optionally substituted by 1-5 independent R3 substituents; and the other variables are as described above for Formula (I).
substituents; X
is heterocyclyl or heteroaryl optionally substituted by 1-5 independent RZ' substituents; A is heteroaryl optionally substituted by 1-5 independent R3 substituents; and the other variables are as described above for Formula (I).
[25] In still another embodiment of this one aspect, the present invention is directed to a compound represented by Formula (1), or a pharmaceutically acceptable salt or N-oxide thereof, wherein Y is cyclohexyl optionally substituted by 1-5 independent Ra substituents; X is heterocyclyl or heteroaryl optionally substituted by 1-5 independent RZl DN
substituents; A is ; and the other variables are as described above for Formula (I).
substituents; A is ; and the other variables are as described above for Formula (I).
[26] In yet another embodiment of this one aspect, the present invention is directed to a compound represented by Formula (I), or a pharmaceutically acceptable salt or N-oxide thereof, wherein Y is cyclohexyl optionally substituted by 1-5 independent RZ
D/N
substituents; X is heterocyclyl or heteroaryl; R' is hydrogen; A is and the other variables are as described above for Formula (I).
D/N
substituents; X is heterocyclyl or heteroaryl; R' is hydrogen; A is and the other variables are as described above for Formula (I).
[27] In another embodiment of this one aspect, the present invention is directed to a compound represented by Formula (I), or a pharmaceutically acceptable salt or N-oxide thereof, wherein Y is cyclohexyl optionally substituted by 1-5 independent Rz substituents; X
is heterocyclyl or heteroaryl optionally substituted by 1-5 independent RZ' substituents; R1 is C1_6a1ky1; and the other variables are as described above for Formula (I).
is heterocyclyl or heteroaryl optionally substituted by 1-5 independent RZ' substituents; R1 is C1_6a1ky1; and the other variables are as described above for Formula (I).
[28] In yet still another embodiment of this one aspect, the present invention is directed to a compound represented by Formula (I), or a pharmaceutically acceptable salt or N-oxide thereof, wherein Y is cyclohexyl optionally substituted by 1-5 independent R2 substituents; X is heterocyclyl optionally substituted by 1-5 independent R21 substituents; R' is C0_6a1ky1; and the other variables are as described above for Formula (1).
[29] In another embodiment of this one aspect, the present invention is directed to a compound represented by Formula (1), or a pharmaceutically acceptable salt or N-oxide thereof, wherein Y is cyclohexyl optionally substituted by 1-5 independent RZ
substituents; X
is heteroaryl optionally substituted by 1-5 independent R21 substitiuents; R' is Co_6alkyl; and the other variables are as described above for Formula (I).
substituents; X
is heteroaryl optionally substituted by 1-5 independent R21 substitiuents; R' is Co_6alkyl; and the other variables are as described above for Formula (I).
[30] In a second aspect, the present invention is directed to a compound represented by Formula (I), or a pharmaceutically acceptable salt or N-oxide thereof, wherein Y is heteroaryl optionally substituted by 1-5 independent RZ substituents; X
is heterocyclyl optionally substituted by 1-5 independent R21 substituents; and the other variables are as described above for Formula (I).
is heterocyclyl optionally substituted by 1-5 independent R21 substituents; and the other variables are as described above for Formula (I).
[31] In an embodiment of this second aspect, the present invention is directed to a compound represented by Formula (1), or a pharmaceutically acceptable salt or N-oxide thereof, wherein Y is heteroaryl optionally substituted by 1-5 independent R2 substituents; X
is heterocyclyl optionally substituted by 1-5 independent R21 substituents; R' is C0_6alkyl; A is heteroaryl optionally substituted by 1-5 independent R3 substituents; and the other variables are as described above for Formula (1).
is heterocyclyl optionally substituted by 1-5 independent R21 substituents; R' is C0_6alkyl; A is heteroaryl optionally substituted by 1-5 independent R3 substituents; and the other variables are as described above for Formula (1).
[32] In an embodiment of this second aspect, the present invention is directed to a compound represented by Formula (I), or a pharmaceutically acceptable salt or N-oxide thereof, wherein Y is heteroaryl optionally substituted by 1-5 independent R2 substituents; X
D/N
is heterocyclyl optionally substituted by 1-5 independent R21 substituents; A
is and the other variables are as described above for Formula (1).
D/N
is heterocyclyl optionally substituted by 1-5 independent R21 substituents; A
is and the other variables are as described above for Formula (1).
[33] In an embodiment of this second aspect, the present invention is directed to a compound represented by Formula (1), or a pharmaceutically acceptable salt or N-oxide thereof, wherein Y is heteroaryl optionally substituted by 1-5 independent Rz substituents; X
is heterocyclyl optionally substituted by 1-5 independent R21 substituents; Rl is hydrogen; A
N
is and the other variables are as described above for Formula (1).
is heterocyclyl optionally substituted by 1-5 independent R21 substituents; Rl is hydrogen; A
N
is and the other variables are as described above for Formula (1).
[34] The present invention includes the following compounds:
N-1,4-dioxaspiro[4.5] dec-8-yl-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
cis-N-1-oxa-4-thiaspiro[4.5]dec-8-yl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
trans-N-l-oxa-4-thi aspiro [4. 5] dec- 8-yl-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(2-methyl-3 -oxo-1,2-diazaspiro [4.5 ] dec-8-yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
trans-N-(2-benzyl-3 -oxo-1, 2-diazaspiro [4.5] dec-8-yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
cis-N-(1,4-dimethyl-5-oxo-1,4-diazaspiro[5.5]undec-9-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
trans-N-(1,4-dimethyl-5-oxo-1,4-diazaspiro[5.5]undec-9-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
cis-N-( 3'-oxo -3',4'-dihydro-1'H-spiro [cyc lohexane-1, 2'-quinoxalin] -4-yl)-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
trans-N-( 3'-oxo-3',4'-dihydro-1'H-spiro [cyc lohexane-1, 2'-quinoxalin] -4-yl) -3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(3 -oxo-2-azaspiro [4.5] dec-8 -yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-1,4-dioxaspiro [4.5 ] dec-8-yl-4-methyl-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
trans-N-(2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(3 -methyl-2,4-dioxo-1, 3 -diazaspiro [4.5] dec-8-yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N- [3 -(3 -methylbutyl)-2, 4-dioxo-1, 3 -diazaspiro [4.5 ] dec-8 -yl] -3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(1'-methyl-2-oxo-1,2-dihydrospiro [indole-3,4'-piperidin] -5 -yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(2'-oxo-1',2'-dihydrospiro[ 1,3-dioxolane-2,3'-indol]-5'-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-1',2'-dihydrospiro[ 1,3 -dioxolane-2,3'-indol]-5'-yl-3 -[(pyridin-4-ylmethyi)amino]thiophene-2-carboxarnide;
N-(2-oxo-1,2,2',3', 5',6'-hexahydrospiro [indole-3,4'-pyran]-5-y1)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(2'-oxo-1',2'-dihydrospiro[ 1,3-dithiolane-2,3'-indol]-5'-yl)-3 -[(quinolin-ylmethyl)amino]thiophene-2-carboxamide;
N-(1,3-dimethyl-2'-oxo-1',2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
3 - [ (quinolin-4-ylmethyl) amino] -N-(1,1', 3 -trimethyl-2'-oxo- 1',2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)thiophene-2-carboxamide;
N-(2'-oxo-1', 2'-dihydro spiro [ 1, 3-di oxane-2, 3'-indol] -5'-yl) -3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
4-methyl-N-(2'-oxo-1',2'-dihydrospiro[ 1,3-dioxolane-2,3'-indol]-5'-yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
4-methyl-N-(2'-oxo-1',2'-dihydrospiro[1,3-dithiolane-2,3'-indol]-5'-yl) -3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(1,3-dimethyl-2'-oxo-1',2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)-4-methyl-3 - [(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
4-methyl-3 -[(quinolin-4-ylmethyl) amino] -N-(1,1', 3-trimethyl-2'-oxo- l', 2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)thiophene-2-carboxamide or a pharmaceutically acceptable salt, or N-oxide, thereof.
N-1,4-dioxaspiro[4.5] dec-8-yl-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
cis-N-1-oxa-4-thiaspiro[4.5]dec-8-yl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
trans-N-l-oxa-4-thi aspiro [4. 5] dec- 8-yl-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(2-methyl-3 -oxo-1,2-diazaspiro [4.5 ] dec-8-yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
trans-N-(2-benzyl-3 -oxo-1, 2-diazaspiro [4.5] dec-8-yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
cis-N-(1,4-dimethyl-5-oxo-1,4-diazaspiro[5.5]undec-9-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
trans-N-(1,4-dimethyl-5-oxo-1,4-diazaspiro[5.5]undec-9-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
cis-N-( 3'-oxo -3',4'-dihydro-1'H-spiro [cyc lohexane-1, 2'-quinoxalin] -4-yl)-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
trans-N-( 3'-oxo-3',4'-dihydro-1'H-spiro [cyc lohexane-1, 2'-quinoxalin] -4-yl) -3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(3 -oxo-2-azaspiro [4.5] dec-8 -yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-1,4-dioxaspiro [4.5 ] dec-8-yl-4-methyl-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
trans-N-(2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(3 -methyl-2,4-dioxo-1, 3 -diazaspiro [4.5] dec-8-yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N- [3 -(3 -methylbutyl)-2, 4-dioxo-1, 3 -diazaspiro [4.5 ] dec-8 -yl] -3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(1'-methyl-2-oxo-1,2-dihydrospiro [indole-3,4'-piperidin] -5 -yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(2'-oxo-1',2'-dihydrospiro[ 1,3-dioxolane-2,3'-indol]-5'-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-1',2'-dihydrospiro[ 1,3 -dioxolane-2,3'-indol]-5'-yl-3 -[(pyridin-4-ylmethyi)amino]thiophene-2-carboxarnide;
N-(2-oxo-1,2,2',3', 5',6'-hexahydrospiro [indole-3,4'-pyran]-5-y1)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(2'-oxo-1',2'-dihydrospiro[ 1,3-dithiolane-2,3'-indol]-5'-yl)-3 -[(quinolin-ylmethyl)amino]thiophene-2-carboxamide;
N-(1,3-dimethyl-2'-oxo-1',2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
3 - [ (quinolin-4-ylmethyl) amino] -N-(1,1', 3 -trimethyl-2'-oxo- 1',2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)thiophene-2-carboxamide;
N-(2'-oxo-1', 2'-dihydro spiro [ 1, 3-di oxane-2, 3'-indol] -5'-yl) -3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
4-methyl-N-(2'-oxo-1',2'-dihydrospiro[ 1,3-dioxolane-2,3'-indol]-5'-yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
4-methyl-N-(2'-oxo-1',2'-dihydrospiro[1,3-dithiolane-2,3'-indol]-5'-yl) -3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(1,3-dimethyl-2'-oxo-1',2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)-4-methyl-3 - [(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
4-methyl-3 -[(quinolin-4-ylmethyl) amino] -N-(1,1', 3-trimethyl-2'-oxo- l', 2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)thiophene-2-carboxamide or a pharmaceutically acceptable salt, or N-oxide, thereof.
[35] The present invention is also directed to a method of treating hyperproliferative disorders, including breast cancer, head cancer, or neck cancer, gastrointestinal cancer, leulcemia, ovarian, bronchial, lung, or pancreatic cancer, mastocytosis/mast cell leukemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leulcemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma, by administering an effective amount of a compound represented by Formula (1), or a pharmaceutically acceptable salt thereof.
[36] As used herein, "C0_6alkyl" is used to mean an alkyl having 0-6 carbons -that is, 0, 1, 2, 3, 4, 5, or 6 carbons in a straight or branched configuration. An alkyl having no carbon is hydrogen when the alkyl is a terminal group. An alkyl having no carbon is a direct bond when the alkyl is a bridging (connecting) group.
[37] As used herein unless otherwise specified, "alkyl", "alkenyl", and "alkynyl"
includes straight or branched configurations. Lower alkyls, alkenyls, and alkynyls have 1-6 carbons. Higher allcyls, alkenyls, and alkynyls have more than 6 carbons.
includes straight or branched configurations. Lower alkyls, alkenyls, and alkynyls have 1-6 carbons. Higher allcyls, alkenyls, and alkynyls have more than 6 carbons.
[38] As used herein unless otherwise specified, "halogen" is fluorine, chlorine, bromine or iodine.
[39] As used herein unless otherwise specified, "substituted" is used to mean having 1-5 independent Co_6alkyl, halogen, nitro, cyano, haloalkyl, C0_6alkoxy, C0_6alkylthio, or C0_6alkylamino substituents [40] As used herein unless otherwise specified, "haloalkyl" includes alkyl groups substituted with one or more halogens, for example, chloromethyl, 2-bromoethyl, 3-iodopropyl, trifluoromethyl, perfluoropropyl, 8-chlorononyl, and the like.
[41] As used herein unless otherwise specified, the terms "aryl" and "ar" are well known to chemists and include, for example, phenyl and naphthyl, as well as phenyl with one or more short alkyl groups (tolyl, xylyl, mesityl, cumenyl, di(t-butyl)phenyl). Phenyl, naphthyl, tolyl, and xylyl are preferred. "Substituted aryl" is an aryl substituted with suitable substituents such as, for example, acyl, substituted acyl, N-protected piperazinylsulfonyl, piperazinylsulfonyl, N-C1_6alkylpiperazinylsulfonyl, hydroxyC1_6alkyl, heterocyclyl, halogen, nitro, amino, C1_6allcylamino, cyano, or C1_6alkoxy.
[42] As used herein unless otherwise specified, the term "cycloalkyl" is well lrnown to chemists and includes cyclic aliphatic ring structures, optionally substituted with allcyl, hydroxyl, oxo, and halo, such as cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl, 2-hydroxycyclopentyl, cyclopentanonyl, cyclohexyl, 4-chlorocyclohexyl, cycloheptyl, cyclooctyl, and the like.
[43] As used herein unless otherwise specified, the term "cycloalkyl" is well lrnown to chemists and includes cyclic aliphatic ring structures having at least one ethylenic bond, optionally substituted with alkyl, hydroxyl, oxo, and halo, for example, methylcyclopropenyl, trifluoromethylcyclopropenyl, cyclopentenyl, cyclohexenonyl, cyclohexenyl, 1,4-cyclohexadienyl, and the like.
[44] As used herein unless otherwise specified, "heterocyclyl" is well known to chemists and includes unsaturated, mono or polycyclic heterocyclic groups containing at least one N, S or 0 hetero-ring atom such as, for example, tetrahydrofuranyl, tetrahydrofuryl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, thiolanyl, morpholinyl, piperazinyl, homopiperazinyl, dioxolanyl, dioxanyl, indolinyl, or chromanyl and the like.
Such heterocyclyls can be suitably substituted with lower alkyl or oxo substituents.
Such heterocyclyls can be suitably substituted with lower alkyl or oxo substituents.
[45] As used herein unless otherwise specified, "heteroaryl" is well known to chemists and includes partially saturated, mono or polycyclic heterocyclic groups containing at least one N, S or 0 hetero-ring atom such as, for example, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl, pyrrolidinyl, indolyl, indolinyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, imidazopyridyl, indazolyl, benzotriazolyl, tetrazolo-pyridazinyl, pyranyl, furyl, thienyl, oxazolyl, isoxazolyl, oxazolyl, benzofuranyl, benzoxazolyl, benzoxadiazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, benzothiazolyl, benzothiadiazolyl, benzofuranyl, or benzodioxyl, imidazolyl, pyrrolyl, oxadiazolyl, quinolyl, benzotriazolyl, or benzothienyl and the lilce. Such heterocyclyls can be suitably substituted with lower alkyl or oxo substituents.
[46] As used herein unless otherwise specified, "heterocycloalkenyl" includes mono or polycyclic heterocyclic groups having at least one ethylenic bond and containing at least one N, S or 0 hetero-ring atom such as, for example, dihydropyranyl, dihydrofuran, pyrrolinyl or the like. Such heterocycloalkenyls can be suitably substituted with lower alkyl or oxo substituents.
[47] As used herein unless otherwise specified, "acyl" includes for example, carboxy, esterified carboxy, carbamoyl, lower alkylcarbamoyl, lower alkanoyl, aroyl, heterocyclylcarbonyl, and the lilce. Esterified carboxy includes substituted or unsubstituted lower alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, t-butoxycarbonyl, hexyloxycarbonyl, 2-iodoethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, dimethylaminopropoxycarbonyl, dimethylaminoethoxycarbonyl;
substituted or unsubstituted aryloxycarbonyl such as phenoxycarbonyl, 4-nitrophenoxycarbonyl, 2-naphthyloxycarbonyl; substituted or unsubstituted ar(lower)alkoxycarbonyl such as benzyloxycarbonyl, phenethyloxycarbonyl, benzhydryloxycarbonyl, 4-nitrobenzyloxycarbonyl, 3-methoxy-4-nitrobenzyloxycarbonyl;
and N-containing heterocyclyloxycarbonyl such as N-methylpiperidyloxycarbonyl and the like.
substituted or unsubstituted aryloxycarbonyl such as phenoxycarbonyl, 4-nitrophenoxycarbonyl, 2-naphthyloxycarbonyl; substituted or unsubstituted ar(lower)alkoxycarbonyl such as benzyloxycarbonyl, phenethyloxycarbonyl, benzhydryloxycarbonyl, 4-nitrobenzyloxycarbonyl, 3-methoxy-4-nitrobenzyloxycarbonyl;
and N-containing heterocyclyloxycarbonyl such as N-methylpiperidyloxycarbonyl and the like.
[48] As used herein unless otherwise specified, "C0_6alkylhydrazino" may be 2-mono or 2,2-di(C0_6alkyl)hydrazino such as 2-methylhydrazino, 2,2-dimethylhydrazino, 2-ethylhydrazino, hydrazine, 2,2-diethylhydrazino, or the like.
[49] As used herein unless otherwise specified, alkylamino such as "Cl_ 6alkylamino" may be mono or dialkylamino such as methylamino, dimethylamino, N-methylethylamino or the like. Similarly, other amino groups such as acylamino are understood to include a Co_6alkyl at the unspecified amino bond site (one being to the acyl, the second forming a connection to the core structure, and the third unspecified).
[50] As used herein unless otherwise specified, "arCO_6alkylamino" may be mono or disubstitutedamino such as anilino, benzylamino, N-methylanilino, N-benzylmethylamino or the like.
[51] As used herein unless otherwise specified, "silyl" includes alkyl and aryl substituted silyl groups such as, for example, triethylsilyl, t-butyldiphenylsilyl, or the like.
[52] As used herein unless otherwise specified, "siloxy" includes alkyl and aryl substituted silyloxy groups such as, for example, triethylsilyloxy, t-butyldiphenylsilyloxy, or the like.
[53] As used herein unless otherwise specified, "sulfonyloxy" includes sulfonyloxy groups substituted with aryl, substituted aryl, or alkyl such as, for example, benzenesulfonyl, tosyl, mesyl or the like.
[54] As used herein unless otherwise specified, "heterocyclylamino" includes unsaturated, mono or polycyclic heterocyclic groups containing at least one N-ring atom which is attached to an amino group such as, for example, 1-aminopiperidine, 1-aminoinorpholine, 1-amino-4-methylpiperazine or the like.
[55] As used herein unless otherwise specified (for example, by a dash marking the point of attachment), chemical group names comprised of multiple chemical terms are used according to standard chemical convention, wherein each term modifies the following term and wherein the rightmost term forms a covalent bond with the structure to which the substituent is attached. For example, aralkylamino includes benzylamino and phenethylamino attached through the amino nitrogen, but not toluidino or N-methylanilino groups.
[56) When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the lilce. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, methanesulfonic, and tartaric acids.
[57] The pharmaceutical compositions of the present invention or used by the methods of the present invention comprise a compound represented by Formula (I) (or a pharmaceutically acceptable salt or N-oxide thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants.
The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
[58] In practice, the compounds represented by Formula (I), or pharmaceutically acceptable salts or N-oxides thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration. E.g., oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion, or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compound represented by Formula (I), or a pharmaceutically acceptable salt or N-oxide thereof, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both.
The product can then be conveniently shaped into the desired presentation.
Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion, or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compound represented by Formula (I), or a pharmaceutically acceptable salt or N-oxide thereof, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both.
The product can then be conveniently shaped into the desired presentation.
[59] Thus, the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt or N-oxide of Formula (I). The compounds of Formula (1), or pharmaceutically acceptable salts or N-oxides thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
[60] The pharmaceutical compositions of this invention include a pharmaceutically acceptable liposomal formulation containing a compound of Formula (I) or a pharmaceutically acceptable salt or N-oxide thereof.
[61] The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.
[62] In preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques.
[63] A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent or other such excipient. These excipients may be, for example, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia;
and lubricating agents, for example, magnesium stearate, stearic acid or talc.
The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer time. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be used.
Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent or other such excipient. These excipients may be, for example, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia;
and lubricating agents, for example, magnesium stearate, stearic acid or talc.
The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer time. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be used.
[64] In hard gelatin capsules, the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. In soft gelatin capsules, the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient.
[65] For example, a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material, which may vary from about 5 to about 95 percent of the total composition. Unit dosage forms will generally contain between from about 1mg to about 2g of the active ingredient, typically 25mg, 50mg, 100mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or 1000mg.
[66] Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water.
A suitable surfactant can be included such as, for example, hydroxypropylcellulose.
Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
A suitable surfactant can be included such as, for example, hydroxypropylcellulose.
Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
[67] Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
[68] Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula (I) of this invention, or a pharmaceutically acceptable salt or N-oxide thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt% to about 10wt% of the compound, to produce a cream or ointment having a desired consistency.
[69] Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds.
[70] In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like.
Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound described by Formula (I), or pharmaceutically acceptable salts or N-oxides thereof, may also be prepared in powder or liquid concentrate form.
Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound described by Formula (I), or pharmaceutically acceptable salts or N-oxides thereof, may also be prepared in powder or liquid concentrate form.
[71] Generally, dosage levels on the order of from about 0.01mg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5mg to about 10g per patient per day. For example, breast cancer, head and neck cancers, and gastrointestinal cancer such as colon, rectal or stomach cancer may be effectively treated by the administration of from about 0.01 to 100mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 7g per patient per day.
[72] Similarly, leukemia, ovarian, bronchial, lung, and pancreatic cancer may be effectively treated by the administration of from about 0.01 to 100mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 7g per patient per day.
[73] Mastocytosis/ mast cell leukemia, gastrointestinal stromal tumors (GIST), small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leulcemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma may be effectively treated by the administration of from about 0.01 to 100mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 7g per patient per day.
[74] It is understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
[75] The compounds of the present invention, or pharmaceutically acceptable salts or N-oxides thereof, can also be effectively administered in conjunction with other cancer therapeutic compounds. For example, cytotoxic agents and angiogenesis inhibiting agents can be advantageous co-agents with the compounds of the present invention.
Accordingly, the present invention includes compositions comprising the compounds represented by Formula (1), or a pharmaceutically acceptable salt or N-oxide thereof, and a cytotoxic agent or an angiogenesis-inhibiting agent. The amounts of each can be therapeutically effective alone - in which case the additive effects can overcome cancers resistant to treatment by monotherapy. The amounts of any can also be subtherapeutic - to minimize adverse effects, particularly in sensitive patients.
Accordingly, the present invention includes compositions comprising the compounds represented by Formula (1), or a pharmaceutically acceptable salt or N-oxide thereof, and a cytotoxic agent or an angiogenesis-inhibiting agent. The amounts of each can be therapeutically effective alone - in which case the additive effects can overcome cancers resistant to treatment by monotherapy. The amounts of any can also be subtherapeutic - to minimize adverse effects, particularly in sensitive patients.
[76] It is understood that the treatment of cancer depends on the type of cancer.
For example, lung cancer is treated differently as a first line therapy than are colon cancer or breast cancer treated. Even within lung cancer, for example, first line therapy is different from second line therapy, which in turn is different from third line therapy.
Newly diagnosed patients might be treated with cisplatinum containing regimens. Were that to fail, they move onto a second line therapy such as a taxane. Finally, if that failed, they might get a tyrosine kinase EGFR inhibitor as a third line therapy. Further, The regulatory approval process differs from country to country. Accordingly, the accepted treatment regimens can differ from country to country. Nevertheless, the compounds of the present invention, or pharmaceutically acceptable salts or N-oxides thereof, can be beneficially co-administered in conjunction or combination with other such cancer therapeutic compounds. Such other compounds include, for example, a variety of cytotoxic agents (alkylators, DNA
topoisomerase inhibitors, antimetabolites, tubulin binders); inhibitors of angiogenesis; and different other forms of therapies including kinase inhibitors such as Tarceva, monoclonal antibodies, and cancer vaccines. Other such compounds that can be beneficially co-administered with the compounds of the present invention include doxorubicin, vincristine, cisplatin, carboplatin, gemcitabine, and the taxanes. Thus, the compositions of the present invention include a compound according to Formula (I), or a pharmaceutically acceptable salt or N-oxide thereof, and an anti-neoplastic, anti-tumor, anti-angiogenic, or chemotherapeutic agent.
For example, lung cancer is treated differently as a first line therapy than are colon cancer or breast cancer treated. Even within lung cancer, for example, first line therapy is different from second line therapy, which in turn is different from third line therapy.
Newly diagnosed patients might be treated with cisplatinum containing regimens. Were that to fail, they move onto a second line therapy such as a taxane. Finally, if that failed, they might get a tyrosine kinase EGFR inhibitor as a third line therapy. Further, The regulatory approval process differs from country to country. Accordingly, the accepted treatment regimens can differ from country to country. Nevertheless, the compounds of the present invention, or pharmaceutically acceptable salts or N-oxides thereof, can be beneficially co-administered in conjunction or combination with other such cancer therapeutic compounds. Such other compounds include, for example, a variety of cytotoxic agents (alkylators, DNA
topoisomerase inhibitors, antimetabolites, tubulin binders); inhibitors of angiogenesis; and different other forms of therapies including kinase inhibitors such as Tarceva, monoclonal antibodies, and cancer vaccines. Other such compounds that can be beneficially co-administered with the compounds of the present invention include doxorubicin, vincristine, cisplatin, carboplatin, gemcitabine, and the taxanes. Thus, the compositions of the present invention include a compound according to Formula (I), or a pharmaceutically acceptable salt or N-oxide thereof, and an anti-neoplastic, anti-tumor, anti-angiogenic, or chemotherapeutic agent.
[77] The compounds of the present invention, or pharmaceutically acceptable salts or N-oxides thereof, can also be effectively administered in conjunction with other therapeutic compounds, aside from cancer therapy. For example, therapeutic agents effective to ameliorate adverse side-effects can be advantageous co-agents with the compounds of the present invention.
[78] C-KIT H526 Cell Assay Protocol [79] I. Assay for inhibition of c-Kit in intact cells [80] The ability of compounds to inhibit the tyrosine kinase activity of c-Kit was determined in a cell-based ELISA assay using the H526 cell line (ATCC # CRL-5 811), which was originally derived from a human small cell lung cancer. The assay determines the ability of compounds to block ligand-stimulated tyrosine phosphorylation of the wild-type c-Kit receptor protein that is endogenously expressed in H526 cells. Cells are pre-incubated with compounds at various concentrations prior to addition of stem cell factor (SCF), the ligand for the c-Kit receptor tyrosine kinase. Cell lysates are then prepared and the c-Kit protein is captured onto a c-Kit antibody-coated 96-well ELISA plate. The phosphotyrosine content of the receptor protein is then monitored by quantitation of the degree of binding of an antibody that recognizes only the phosphorylated tyrosine residues within the captured protein. The antibody used has a reporter enzyme (e.g. horseradish peroxidase, HRP) covalently attached, such that binding of antibody to phosphorylated c-Kit can be determined quantitatively by incubation with an appropriate HRP substrate.
[81] The stock reagents used are as follows:
[82] Cell lysis buffer:
50mM Tris-HCI, pH 7.4 150mM NaC1 10% Glycerol 1% Triton X-100 0.5mM EDTA
1 g/mL leupeptin 1 g/mL aprotinin 1mM Sodium orthovanadate [83] Anti c-Kit antibody:
0.5 gImL anti c-Kit Ab-3 (Lab Vision, catalog #MS289P1 ) in 50mM
Sodium bicarbonate, pH 9.
50mM Tris-HCI, pH 7.4 150mM NaC1 10% Glycerol 1% Triton X-100 0.5mM EDTA
1 g/mL leupeptin 1 g/mL aprotinin 1mM Sodium orthovanadate [83] Anti c-Kit antibody:
0.5 gImL anti c-Kit Ab-3 (Lab Vision, catalog #MS289P1 ) in 50mM
Sodium bicarbonate, pH 9.
[84] ELISA Assayplates:
ELISA assay plates are prepared by addition of 100 L of anti c-Kit antibody to each well of a 96-well Microlite-2 plate (Dynex, catalog # 7417), followed by incubation at 37 C for 2h. The wells are then washed twice with 300 L wash buffer.
ELISA assay plates are prepared by addition of 100 L of anti c-Kit antibody to each well of a 96-well Microlite-2 plate (Dynex, catalog # 7417), followed by incubation at 37 C for 2h. The wells are then washed twice with 300 L wash buffer.
[85] Plate wash buffer:
PBS containing 0.5% Tween-20 (PBST) [86] Cell assay medium:
RPMI with 0.1% BSA
PBS containing 0.5% Tween-20 (PBST) [86] Cell assay medium:
RPMI with 0.1% BSA
[87] pY20-HRP:
25ng/mL pY20-HRP (Calbiochem, catalog # 525320) in PBS, containing 0.5% Tween-20, 5% BSA, 1 mM Sodium orthovanadate [88] HRP substrate:
Chemoluminescent detection reagent (Pierce, catalog # 37075) [89] Assay protocol [90] Cultures of H526 cells, growing in RPMI with 10% fetal calf serum, were collected by centrifugation, washed twice with PBS, and suspended in cell assay medium.
Cells were then distributed into a V-bottom 96-well plate at 7.5 x 104 cells per well in 100 L
cell assay medium.
25ng/mL pY20-HRP (Calbiochem, catalog # 525320) in PBS, containing 0.5% Tween-20, 5% BSA, 1 mM Sodium orthovanadate [88] HRP substrate:
Chemoluminescent detection reagent (Pierce, catalog # 37075) [89] Assay protocol [90] Cultures of H526 cells, growing in RPMI with 10% fetal calf serum, were collected by centrifugation, washed twice with PBS, and suspended in cell assay medium.
Cells were then distributed into a V-bottom 96-well plate at 7.5 x 104 cells per well in 100 L
cell assay medium.
[91] Compound dilutions were prepared from 10mM DMSO stocks by dilution in cell assay medium, the final concentration of DMSO in the assay being 0.1%. To compound incubation wells, 50 L of the test compound was added (compounds are assayed at concentrations between 0.1nM and 100 M); to positive and negative control wells, 50 L cell assay medium containing 0.1 % DMSO was added. The cells were then incubated with compound at 37 C for 3h. SCF (R&D Systems, catalog #255-SC-010) was then added in order to stimulate the c-Kit receptor and induce its tyrosine phosphorylation.
Then, 10 L of a 1.6 g/mL solution of SCF in cell assay medium was added to all wells apart from the negative control wells, and the cells were incubated for an additional 15min at 37 C.
Following the addition of ice-cold PBS, the plate was centrifuged at 1000rpm for 5min, the medium removed by aspiration, and the cell pellet lysed by the addition of 120 L ice-cold cell lysis buffer per well. The plate was kept on ice for 20min and 100 L of the cell lysates from each well were then transferred to the wells of an ELISA assay plate and incubated at 4 C for 16h.
Then, 10 L of a 1.6 g/mL solution of SCF in cell assay medium was added to all wells apart from the negative control wells, and the cells were incubated for an additional 15min at 37 C.
Following the addition of ice-cold PBS, the plate was centrifuged at 1000rpm for 5min, the medium removed by aspiration, and the cell pellet lysed by the addition of 120 L ice-cold cell lysis buffer per well. The plate was kept on ice for 20min and 100 L of the cell lysates from each well were then transferred to the wells of an ELISA assay plate and incubated at 4 C for 16h.
[92] Following incubation of the cell lysates in the ELISA plate, the wells were washed 4 times with 300 L wash buffer, then 100 L of the phosphotyrosine detection antibody pY20-HRP was added to each well and the plate incubated at rt for 2h.
The wells were then washed 4 times with 300 L wash buffer. Then, 50 L of the chemiluminescent HRP substrate was added to each well for luminometric quantitation of the amount of antiphosphotyrosine-HRP conjugate bound to the plate.
The wells were then washed 4 times with 300 L wash buffer. Then, 50 L of the chemiluminescent HRP substrate was added to each well for luminometric quantitation of the amount of antiphosphotyrosine-HRP conjugate bound to the plate.
[93] Comparison of the assay signals obtained in the presence of compound with those of the positive and negative controls (cells incubated in the presence or absence of SCF, with no compound added), allows the degree of inhibition of c-Kit receptor tyrosine phosphorylation to be determined over a range of compound concentrations.
These inhibition values were fitted to a sigmoidal dose-response inhibition curve to determine the IC50 values (i.e. the concentration of compound that inhibits SCF-induced tyrosine phosphorylation of the c-Kit protein by 50%).
These inhibition values were fitted to a sigmoidal dose-response inhibition curve to determine the IC50 values (i.e. the concentration of compound that inhibits SCF-induced tyrosine phosphorylation of the c-Kit protein by 50%).
[94] The EXAMPLES of this invention reduced the ability of Kit to phosphorylate poly(Glu:Tyr) in the above assay, thus demonstrating direct inhibition of the c-Kit receptor tyrosine kinase activity. IC50 values in this assay for the EXAMPLES described below were between 30nM and 15 M. IC50 values in this assay for COMPOUNDS 1-6 were greater than 15 pM.
EXPERIMENTAL
EXPERIMENTAL
[95] The EXAMPLES of the present invention were prepared according to the following procedures:
[96] Referring to the scheme shown below for EXAMPLE 1, reaction of aminothiophene 1 with aldehydes under reducing conditions affords secondary amines such as compound 2 - for example, in the presence of a mixture of triethylsilane and trifluoroacetic acid, or other reagents such as (but not limited to) sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride and hydrogen. Saponification of the resulting ester then gives carboxylic acid of type 3. Compounds such as 3 may then be reacted with amines in the presence of an activating agent to give carboxamides such as EXAMPLE 1.
[97] In the section below, the following abbreviations are used: Me for methyl, Et for ethyl, Ph for phenyl, iPr for isopropyl, Bn for benzyl, THF for tetrahydrofuran, DMF for dimethylformamide, AcOH for acetic acid, EDC for 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, HOAt for 1-hydroxy-7-azabenzotriazole, PCC
for pyridinium chlorochcomate, DMEDA for N,N-dimethylethylenediamine, EtOAc for ethyl acetate, MeCN for acetonitrile, Boc for tertbutyloxycarbnoyl, DMSO for dimethylsulfoxide, DCM for dichloromethane, Ts for toluenesulfonyl, TFA for trifluoroacetic acid, MS for mass spectroscopy, ES for electrospray, rt for room temperature, min for minute, and h for hour.
for pyridinium chlorochcomate, DMEDA for N,N-dimethylethylenediamine, EtOAc for ethyl acetate, MeCN for acetonitrile, Boc for tertbutyloxycarbnoyl, DMSO for dimethylsulfoxide, DCM for dichloromethane, Ts for toluenesulfonyl, TFA for trifluoroacetic acid, MS for mass spectroscopy, ES for electrospray, rt for room temperature, min for minute, and h for hour.
[98] EXAMPLE 1 N-1,4-Dioxaspiro [4.5] dec-8-yl-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide H -N
ES \N-ao 0 0~~
ES \N-ao 0 0~~
[99] EXAMPLE 1 was prepared by the following procedure:
BnoxG
~' ~HCI THFCOH30 ON~.OH DCM O~N~O
HZN 0 C - rt H H
HO(CHZ),OH OBn 0 Hz, Pd/C O-~
p-TsOH, HC(OMe)3 O1''N HN"]:::::~O
H o N N
NH2 1. NaOH, HZO, ~
N MeOH N -Et3SiH 2. HCI =HCI
O TFA/DCM O- FS~\ OH
O O
0~ ' ~ N
HiN H
EDC, HOAt, H
EtNPri 2, CH2CI2 N-ao O OJ
BnoxG
~' ~HCI THFCOH30 ON~.OH DCM O~N~O
HZN 0 C - rt H H
HO(CHZ),OH OBn 0 Hz, Pd/C O-~
p-TsOH, HC(OMe)3 O1''N HN"]:::::~O
H o N N
NH2 1. NaOH, HZO, ~
N MeOH N -Et3SiH 2. HCI =HCI
O TFA/DCM O- FS~\ OH
O O
0~ ' ~ N
HiN H
EDC, HOAt, H
EtNPri 2, CH2CI2 N-ao O OJ
[100] Part 1:
[101] Benzyl 4-hydroxycyclohexylcarbamate (1): A mixture of trans-4-aminocyclohexanol hydrochloride (12.13g, 80mmo1) and K2CO3 (24.32g, 176mmo1) in THF
(160mL) and water (320mL) was cooled to 0 C. A solution of benzyl chloroformate (12.4mL, 88mmol) in THF (16mL) was added drop-wise. The mixture was then stirred at rt for 30min. The mixture was then extracted with ether (200mL) and the organic phase was washed with brine (150mL), dried over MgSO4, filtered, and concentrated in vacuo. The crude product was purified by recrystallization from ether to afford benzyl4-hydroxycyclohexylcarbainate as a white solid. 'H NMR (CDC13, 400MHz): S 1.15-1.25 (m, 2H), 1.35-1.45 (m, 2H), 1.96-2.05 (m, 4H), 3.46-3.53 (m, 1H), 3.58-3.64 (m, 1H), 4.56 (brs, 1H), 5.08 (s, 2H), 7.30-7.36 (m, 5H). MS (ES+): rn/z 250 [M+1].
(160mL) and water (320mL) was cooled to 0 C. A solution of benzyl chloroformate (12.4mL, 88mmol) in THF (16mL) was added drop-wise. The mixture was then stirred at rt for 30min. The mixture was then extracted with ether (200mL) and the organic phase was washed with brine (150mL), dried over MgSO4, filtered, and concentrated in vacuo. The crude product was purified by recrystallization from ether to afford benzyl4-hydroxycyclohexylcarbainate as a white solid. 'H NMR (CDC13, 400MHz): S 1.15-1.25 (m, 2H), 1.35-1.45 (m, 2H), 1.96-2.05 (m, 4H), 3.46-3.53 (m, 1H), 3.58-3.64 (m, 1H), 4.56 (brs, 1H), 5.08 (s, 2H), 7.30-7.36 (m, 5H). MS (ES+): rn/z 250 [M+1].
[102] Part 2:
[103] Benzyl 4-oxocyclohexylcarbamate (2): To a solution of benzyl 4-hydroxycyclohexylcarbamate (9.97g, 40.0mmo1) in CHzCl2 (190mL) was added PCC
(21.90g, 101.6mmol) in portions. The suspension was stirred at rt for 16h and then filtered through a Celite pad. The filtrate was concentrated and the residue was purified by column chromatography (5% MeOH in CH2C12) to yield benzyl 4-oxocyclohexylcarbamate.
IH NMR
(CDC13, 400MHz): S 1.59-1.75 (m, 2H), 2.24 (m, 2H), 2.38-2.47 (m, 4H), 3,.95-4.05 (m, 1 H), 4.78 (brs, 111), 5.12 (s, 2H), 7.32-7.40 (m, 5H). MS (ES+): rn/z 248 [M+1].
(21.90g, 101.6mmol) in portions. The suspension was stirred at rt for 16h and then filtered through a Celite pad. The filtrate was concentrated and the residue was purified by column chromatography (5% MeOH in CH2C12) to yield benzyl 4-oxocyclohexylcarbamate.
IH NMR
(CDC13, 400MHz): S 1.59-1.75 (m, 2H), 2.24 (m, 2H), 2.38-2.47 (m, 4H), 3,.95-4.05 (m, 1 H), 4.78 (brs, 111), 5.12 (s, 2H), 7.32-7.40 (m, 5H). MS (ES+): rn/z 248 [M+1].
[104] Part 3:
[105] Benzy11,4-dioxaspiro[4.5]dec-8-ylcarbamate (3): To a solution of benzyl 4-oxocyclohexylcarbamate (495mg, 2.0mmo1), ethylene glycol (248mg, 4.0mmo1) and HC(OMe)3 (0.44mL, 4.0mmo1) in dichloromethane (5mL) was addedp-TsOH.H20 (19mg, 0.1 mmol). The mixture was stirred at rt overnight. The reaction was concentrated in vacuo and the residue was purified by silica gel chromatography (1% MeOH in CH2C12) to yield benzyl 1,4-dioxaspiro[4.5]dec-8-ylcarbamate. 'H NMR (CDC13, 400MHz): S 1.45-1.54 (m, 2H), 1.60-1.68 (m, 2H), 1.70-1.77 (m, 2H), 1.92-1.99 (m, 2H), 3.58-3.62 (m, 1H), 3.94 (s, 4H), 4.63 (brs, 1H), 5.09 (s, 2H), 7.30-7.36 (m, 5H). MS (ES+): ni/z 292 [M+1].
[106] Part 4:
[107] 1,4-Dioxaspiro[4.5]dec-8-ylamine (4): To a solution of benzyl 1,4-dioxaspiro[4.5]dec-8-ylcarbamate (475mg, 1.6mmo1) in methanol (8mL) was added 10%
Pd/C (50mg). The mixture was then evacuated and backfilled with N2 atmosphere (2x) and then evacuated and backfilled with H2 atmosphere (2x). The reaction was then stirred at rt overnight. The catalyst was removed by filtration through a Celite pad and the filtrate was concentrated to dryness to yield crude 1,4-dioxaspiro[4.5]dec-8-ylamine, which was used directly in Part 7 without further purification.
Pd/C (50mg). The mixture was then evacuated and backfilled with N2 atmosphere (2x) and then evacuated and backfilled with H2 atmosphere (2x). The reaction was then stirred at rt overnight. The catalyst was removed by filtration through a Celite pad and the filtrate was concentrated to dryness to yield crude 1,4-dioxaspiro[4.5]dec-8-ylamine, which was used directly in Part 7 without further purification.
[108] Part 5:
[109] Methyl 3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxylate (18): A
mixture of 3-amino-thiophene-2-carboxylic acid methyl ester (5g, 31.8mmo1) and quinoline-carboxaldehyde (5.25g, 33.4mmo1) in TFA/CH2C12 (75mL, 75mL) was heated at 50 C for 3.5h. The solution was cooled in an ice bath and triethylsilane (10.2mL, 63.6nunol) was added drop-wise over 5min. The reaction mixture was stirred at 50 C for 3.5h, cooled to rt, and 500mL of CH2C12 was added. The reaction mixture was basified with lON
NaOH (pH
6-7) followed by sat. NaHCO3 (pH 8). The CH2C121ayer was separated and the aqueous layer was extracted with CH2C12 (2x100mL). The organic extracts were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to yield the crude product, which was triturated with hexane to give pure methyl 3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxylate as white solid. MS (ES): m/z 298.55 (100) [MH+];
'H-NMR (400MHz/CDC13): 8 3.87 (s, 3H), 5.00 (d, J= 4.0 Hz, 2H), 6.48 (d, J=
5.6 Hz, 1H), 7.30 (d, J= 5.6 Hz, 1H), 7.36 (m, 1H), 7.41 (d, J= 4.4 Hz, 1H), 7.62 (t, J=
8.0 Hz, 1H), 7.76 (t, J= 9.6 Hz, 1H), 8.01 (d, J= 8.0 Hz, 1H), 8.17 (d, J= 8.4 Hz, 1H), 8.86 (d, J= 4.4 Hz, 1H).
mixture of 3-amino-thiophene-2-carboxylic acid methyl ester (5g, 31.8mmo1) and quinoline-carboxaldehyde (5.25g, 33.4mmo1) in TFA/CH2C12 (75mL, 75mL) was heated at 50 C for 3.5h. The solution was cooled in an ice bath and triethylsilane (10.2mL, 63.6nunol) was added drop-wise over 5min. The reaction mixture was stirred at 50 C for 3.5h, cooled to rt, and 500mL of CH2C12 was added. The reaction mixture was basified with lON
NaOH (pH
6-7) followed by sat. NaHCO3 (pH 8). The CH2C121ayer was separated and the aqueous layer was extracted with CH2C12 (2x100mL). The organic extracts were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to yield the crude product, which was triturated with hexane to give pure methyl 3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxylate as white solid. MS (ES): m/z 298.55 (100) [MH+];
'H-NMR (400MHz/CDC13): 8 3.87 (s, 3H), 5.00 (d, J= 4.0 Hz, 2H), 6.48 (d, J=
5.6 Hz, 1H), 7.30 (d, J= 5.6 Hz, 1H), 7.36 (m, 1H), 7.41 (d, J= 4.4 Hz, 1H), 7.62 (t, J=
8.0 Hz, 1H), 7.76 (t, J= 9.6 Hz, 1H), 8.01 (d, J= 8.0 Hz, 1H), 8.17 (d, J= 8.4 Hz, 1H), 8.86 (d, J= 4.4 Hz, 1H).
[110] Part 6:
[111] 3-[(Quinolin-4-ylmethyl)amino]thiophene-2-carboxylic acid hydrochloride (19): To a suspension of 3-[(quinolin-4-ylmethyl)-amino]-thiophene-2-carboxylic acid methyl ester (5.OOg, 16.8mmo1) in a mixture of H20 (2OmL) and MeOH
(250mL) was added solid NaOH (6.7g, 167.5mmo1). The reaction mixture was stirred at reflux for 5h. The organic solvent was evaporated under reduced pressure and water (60mL) was added to dissolve the residue. The aqueous solution was washed with ethyl acetate (50mL) and then acidified with 1N HCl to pH 5-6. 3-[(Quinolin-4-ylmethyl)amino]thiophene-2-carboxylic acid hydrochloride precipitated from solution and was collected by filtration.'HNMR (400 MHz/DMSO-d6): S 5.07 (s, 2H), 6.71 (d, J= 4.0 Hz, 1H), 7.36 (d, J= 4.0 Hz, 1H), 7.43 (m, 1H), 7.58 (d, J= 4.0 Hz, 1H), 7.67 (t, J= 8.4 Hz, 1H), 7.80 (t, J= 7.2 Hz, 1H), 8.06 (d, J= 8.4 Hz, 1H), 8.22 (d, J= 8.4 Hz, 1H), 8.83 (d, J=
3.6 Hz, 1H), 12.30 (s, 1H). MS (ES+): 285[MH}].
(250mL) was added solid NaOH (6.7g, 167.5mmo1). The reaction mixture was stirred at reflux for 5h. The organic solvent was evaporated under reduced pressure and water (60mL) was added to dissolve the residue. The aqueous solution was washed with ethyl acetate (50mL) and then acidified with 1N HCl to pH 5-6. 3-[(Quinolin-4-ylmethyl)amino]thiophene-2-carboxylic acid hydrochloride precipitated from solution and was collected by filtration.'HNMR (400 MHz/DMSO-d6): S 5.07 (s, 2H), 6.71 (d, J= 4.0 Hz, 1H), 7.36 (d, J= 4.0 Hz, 1H), 7.43 (m, 1H), 7.58 (d, J= 4.0 Hz, 1H), 7.67 (t, J= 8.4 Hz, 1H), 7.80 (t, J= 7.2 Hz, 1H), 8.06 (d, J= 8.4 Hz, 1H), 8.22 (d, J= 8.4 Hz, 1H), 8.83 (d, J=
3.6 Hz, 1H), 12.30 (s, 1H). MS (ES+): 285[MH}].
[112] Part 7:
[113] N-1,4-Dioxaspiro [4.5] dec-8-y1-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide: To a suspension of 3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxylic acid hydrochloride (96mg, 0.3mmol) and 1,4-dioxaspiro[4.5]dec-8-ylamine (47mg, 0.3mmo1) in dichloroinethane (5mL) was added EDC (72mg, 0.38mmo1), HOAt (0.5M solution in DMF, 0.18mL, 0.091nmol) and i-Pr2NEt (0.16mL). The mixture was stirred at rt for 18h. The reaction was concentrated in vacuo and the residue was purified by silica gel chromatography (5-10% MeOH in dichloromethane) to afford EXAMPLE 1. 1H NMR (CDC13, 400 MHz):
1.56-1.82 (m, 8H), 3.95-4.05 (m, 5H), 4.96 (d, J= 6.4 Hz, 2H), 5.27 (d, br, J=
8.0 Hz, 1H), 6.51 (d, J= 5.2 Hz, 1H), 7.14 (d, J= 4.8 Hz, lH), 7.46 (d, J= 4.0 Hz, 1H), 7.61 (dt, J= 0.8, 8.4 Hz, 1H), 7.75 (dt, J= 1.6, 8.8 Hz, 1H), 7.96 (d, br, J= 5.6 Hz, 1H), 8.02 (d, J= 8.8 Hz, 1H), 8.16 (d, J= 8.4 Hz, 1H), 8.85 (d, J= 4.4 Hz, lH). MS (ES+): m/z 424 [M+1].
1.56-1.82 (m, 8H), 3.95-4.05 (m, 5H), 4.96 (d, J= 6.4 Hz, 2H), 5.27 (d, br, J=
8.0 Hz, 1H), 6.51 (d, J= 5.2 Hz, 1H), 7.14 (d, J= 4.8 Hz, lH), 7.46 (d, J= 4.0 Hz, 1H), 7.61 (dt, J= 0.8, 8.4 Hz, 1H), 7.75 (dt, J= 1.6, 8.8 Hz, 1H), 7.96 (d, br, J= 5.6 Hz, 1H), 8.02 (d, J= 8.8 Hz, 1H), 8.16 (d, J= 8.4 Hz, 1H), 8.85 (d, J= 4.4 Hz, lH). MS (ES+): m/z 424 [M+1].
[114] The following analogues were prepared according to the procedure described above for EXAMPLE 1, using 2-mercaptoethanol instead of ethylene glycol.
[115] EXAMPLE 2 cis-N-1-Oxa-4-thiaspiro[4.5]dec-8-yl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide: MS (ES+) 440 [M+1]
H
N
cciX) O
H
N
cciX) O
[116] EXAMPLE 3 traras-N-l-Oxa-4-thiaspiro[4.5]dec-8-yl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide: MS (ES+) 440 [M+1]
H
N
cIyD
O
H
N
cIyD
O
[117] EXAMPLE 4 N-1,4-Dioxaspiro [4.5 ] dec-8-yl-4-methyl-3 - [(quinolin-4-ylmethyl)amino]
thiophene-2-carboxamide N
H
N
/S~ N_~ O
O
thiophene-2-carboxamide N
H
N
/S~ N_~ O
O
[118] EXAMPLE 4 was prepared according to the procedure described for EXAMPLE 1 using 3-amino-4-methyl-thiophene-2-carboxylic acid methyl ester instead of 3-amino-thiophene-2-carboxylic acid methyl ester: MS (ES+) 438 [M+1].
[119] EXAMPLE 5 cis-N-(1,4-Dimethyl-5-oxo-l,4-diazaspiro [5.5]undec-9-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide H
N H
c I N O
S
O
-N N-~/
N H
c I N O
S
O
-N N-~/
[120] EXAMPLE 5 was prepared according to the procedure described for EXAMPLE 1 using 9-amino-1,4-dimethyl-1,4-diazaspiro[5.5]undecan-5-one (compound 7 in the procedure below) instead of 1,4-dioxaspiro[4.5]dec-8-ylamine. MS (ES+) 478 [M+1].
O CHCI3, NaCN (cat.) O N
OBn Et4N+Cl-, 50 /a NaOH OIBn N ' O~Na DMEDA, DCM ON 0 \ + ~ n N
H H O H
H2, Pd/C H2, Pd/C
MeOH MeOH
O N
N\ + NJ
H2N O HzN
7 g [121] Part 1:
O CHCI3, NaCN (cat.) O N
OBn Et4N+Cl-, 50 /a NaOH OIBn N ' O~Na DMEDA, DCM ON 0 \ + ~ n N
H H O H
H2, Pd/C H2, Pd/C
MeOH MeOH
O N
N\ + NJ
H2N O HzN
7 g [121] Part 1:
[122] Benzy11,4-dimethyl-5-oxo-1,4-diazaspiro[5.5]undec-9-ylcarbamate (5, 6):
A solution of benzyl 4-oxocyclohexylcarbamate (74mg, 0.30mmo1), N,N-dimethylethylenediamine (40mg, 0.45mmol), CHC13 (54mg, 0.45mmol), NaCN (0.9mg, 0.02mmo1), Et4WC1- (1.5mg, 9.0 mo1) in dichloromethane was cooled to 0 C and 50%
aqueous NaOH (0.5mL) was added. The mixture was stirred vigorously at rt for 24h and then poured into a separation funnel. Dichloromethane and water were added. The organic phase was removed and the aqueous solution was extracted with dichloromethane. The combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo to a crude mixture of spiro compounds 5 and 6. The crude mixture was purified by silica gel chromatography (1-5% MeOH in DCM) to yield benzyl 1,4-dimethyl-5-oxo-1,4-diazaspiro[5.5]undec-9-ylcarbamate. Analytical data for cis isomer (5): 'H NMR
(CDC13, 400MHz): 8 1.39-1.47 (m, 2H), 1.80-1.88 (m, 2H), 1.89-2.01 (m, 4H), 2.42 (s, 3H), 2.92 (s, 3H), 3.13 (t, J= 6.0 Hz, 2H), 3.36 (t, J= 6.0 Hz, 2H), 3.57-3.62 (m, 1H), 4.62 (brs, 1H), 5.09 (s, 2H), 7.31-7.37 (m, 5H). MS (ES+): na/z 346 [M+1]. Analytical data for trans isomer (6):
'H NMR (CDC13, 400MHz): 6 1.70-1.77 (m, 4H), 1.84-1.90 (m, 2H), 1.97-2.02 (m, 2H), 2.42 (s, 3H), 2.91 (s, 3H), 3.10 (t, J= 5.6 Hz, 2H), 3.36 (t, J= 5.6 Hz, 2H), 3.75-3.80 (m, 1H), 5.09 (s, 2H), 5.12 (brs, 1H), 7.30-7.36 (m, 5H). MS (ES+): rn/z 346 [M+1].
A solution of benzyl 4-oxocyclohexylcarbamate (74mg, 0.30mmo1), N,N-dimethylethylenediamine (40mg, 0.45mmol), CHC13 (54mg, 0.45mmol), NaCN (0.9mg, 0.02mmo1), Et4WC1- (1.5mg, 9.0 mo1) in dichloromethane was cooled to 0 C and 50%
aqueous NaOH (0.5mL) was added. The mixture was stirred vigorously at rt for 24h and then poured into a separation funnel. Dichloromethane and water were added. The organic phase was removed and the aqueous solution was extracted with dichloromethane. The combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo to a crude mixture of spiro compounds 5 and 6. The crude mixture was purified by silica gel chromatography (1-5% MeOH in DCM) to yield benzyl 1,4-dimethyl-5-oxo-1,4-diazaspiro[5.5]undec-9-ylcarbamate. Analytical data for cis isomer (5): 'H NMR
(CDC13, 400MHz): 8 1.39-1.47 (m, 2H), 1.80-1.88 (m, 2H), 1.89-2.01 (m, 4H), 2.42 (s, 3H), 2.92 (s, 3H), 3.13 (t, J= 6.0 Hz, 2H), 3.36 (t, J= 6.0 Hz, 2H), 3.57-3.62 (m, 1H), 4.62 (brs, 1H), 5.09 (s, 2H), 7.31-7.37 (m, 5H). MS (ES+): na/z 346 [M+1]. Analytical data for trans isomer (6):
'H NMR (CDC13, 400MHz): 6 1.70-1.77 (m, 4H), 1.84-1.90 (m, 2H), 1.97-2.02 (m, 2H), 2.42 (s, 3H), 2.91 (s, 3H), 3.10 (t, J= 5.6 Hz, 2H), 3.36 (t, J= 5.6 Hz, 2H), 3.75-3.80 (m, 1H), 5.09 (s, 2H), 5.12 (brs, 1H), 7.30-7.36 (m, 5H). MS (ES+): rn/z 346 [M+1].
[123] Part 2:
[124] 9-Amino-1,4-dimethyl-1,4-diazaspiro[5.5]undecan-5-one (7): To a solution of benzyl 1,4-dimethyl-5-oxo-1,4-diazaspiro[5.5]undec-9-ylcarbamate (5mg, 0.014mmo1) in methanol (lmL) was added 10% Pd/C (5mg, 4.6 mo1). The solution was then deoxygenated and back filled with N2 atmosphere (repeated 2x). The solution was then degassed and back filled with H2 atmosphere (repeated 2x). The mixture was then stirred under H2 atmosphere at rt overnight. The catalyst was removed by filtration through a Celite pad and the filtrate was concentrated to dryness to give the crude 9-amino-1,4-dimethyl-1,4-diazaspiro[5.5]undecan-5-one, which was used directly in the next step without purification.
[125] EXAMPLE 6 trans-N-(1,4-Dimethyl-5 -oxo-1,4-diazaspiro[5.5]undec-9-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide H
N H
/\N
S ~/
O ~
O~
N
N H
/\N
S ~/
O ~
O~
N
[126] EXAMPLE 6 was prepared according to the procedure described for EXAMPLE 1 using 9-amino-1,4-dimethyl-1,4-diazaspiro[5.5]undecan-5-one (compound 8 in the procedure above) instead of 1,4-dioxaspiro[4.5]dec-8-ylamine. MS (ES+) 478 [M+1].
[127] EXAMPLE 7 cis-N-(3'-Oxo-3',4'-dihydro-1'H-spiro [cyclohexane-1,2'-quinoxalin] -4-yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide -' \
H
N H
/
S N O
O
HN NH
H
N H
/
S N O
O
HN NH
[128] EXAMPLE 7 was prepared according to the procedure described for EXAMPLE 5 using 1,2-phenylenediamine instead of N,N-dimethylethylenediamine.
MS
(ES+) 498 [M+1].
MS
(ES+) 498 [M+1].
[129] EXAMPLE 8 trayis-N-(3'-Oxo-3',4'-dihydro-1'H-spiro [cyclohexane-1,2'-quinoxalin]-4-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide N
H
N N H H
O
o==~ N
H
H
N N H H
O
o==~ N
H
[130] EXAMPLE 8 was prepared according to the procedure described for EXAMPLE 6 using 1,2-phenylenediamine instead of N,N-dimethylethylenediamine.
MS
(ES+) 498 [M+1].
MS
(ES+) 498 [M+1].
[131] COMPOiJND 1 cis-N-(4-Methyl-5-oxo-1,4-diazaspiro[5.5]undec-9-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide S / ~ DN
_ H N H
/S \ N-'19 O
O
HN N-[132] COMPOUND 1 was prepared according to the procedure described for EXAMPLE 6 using N-methylethylenediamine instead of N,N-dimethylethylenediamine. MS
(ES+) 464 [M+1].
_ H N H
/S \ N-'19 O
O
HN N-[132] COMPOUND 1 was prepared according to the procedure described for EXAMPLE 6 using N-methylethylenediamine instead of N,N-dimethylethylenediamine. MS
(ES+) 464 [M+1].
[133] EXAMPLE 9 N-(3 -Oxo-2-azaspiro [4.5] dec-8-yl)-3 -[(quinolin-4-ylmethyl)amino] thiophene-2-carboxamide N
H
N
c#oqo [134] EXAMPLE 9 was prepared according to the procedure described for EXAMPLE 1 using 8-amino-2-azaspiro[4.5]decan-3-one (compound 12 in the procedure below) instead of 1,4-dioxaspiro[4.5]dec-8-ylamine. MS (ES+) 435 [M+1].
Ph P- 0 O 3 ~j--OMe (/
BnOA o Bn0''N -H~O toluene, reflux H~OMe H O
Raney Ni MeN NMe BnO~ ~\ ~-NOZ EtOH
MeNO2 N
reflux H-(~/~(~
CO2Me NH ?' BnO_~ N_'--% H Pd/C H2N -~__/~H
H MeOH O
H
N
c#oqo [134] EXAMPLE 9 was prepared according to the procedure described for EXAMPLE 1 using 8-amino-2-azaspiro[4.5]decan-3-one (compound 12 in the procedure below) instead of 1,4-dioxaspiro[4.5]dec-8-ylamine. MS (ES+) 435 [M+1].
Ph P- 0 O 3 ~j--OMe (/
BnOA o Bn0''N -H~O toluene, reflux H~OMe H O
Raney Ni MeN NMe BnO~ ~\ ~-NOZ EtOH
MeNO2 N
reflux H-(~/~(~
CO2Me NH ?' BnO_~ N_'--% H Pd/C H2N -~__/~H
H MeOH O
[135] Part 1:
[136] Methyl (4-benzyloxycarbonylaminocyclohexylidene)acetate (9): A
solution of benzyl 4-oxocyclohexylcarbamate (1.24g, 5.Ommol) and methyl (triphenylphosphoranylidene)acetate (2.09g, 6.3mmol) in toluene (IOmL) was refluxed for 18h. The solvent was removed in vacuo and the residue was purified by silica gel chromatography (1-5% MeOH in CH2C12) to afford methyl (4-benzyloxycarbonylaminocyclohexylidene)acetate. 'H NMR (CDC13, 400MHz): S 1.28-1.41 (m, 2H), 2.05-2.30 (m, 5H), 3.60-3.64 (m, 1H), 3.09 (s, 3H), 3.76-3.82 (m, 1H), 4.62-4.68 (m, 1H), 5.10 (s, 2H), 5.65 (s, 1H), 7.31-7.37 (m, 5H). MS (ES+): nz/z 304 [M+1].
solution of benzyl 4-oxocyclohexylcarbamate (1.24g, 5.Ommol) and methyl (triphenylphosphoranylidene)acetate (2.09g, 6.3mmol) in toluene (IOmL) was refluxed for 18h. The solvent was removed in vacuo and the residue was purified by silica gel chromatography (1-5% MeOH in CH2C12) to afford methyl (4-benzyloxycarbonylaminocyclohexylidene)acetate. 'H NMR (CDC13, 400MHz): S 1.28-1.41 (m, 2H), 2.05-2.30 (m, 5H), 3.60-3.64 (m, 1H), 3.09 (s, 3H), 3.76-3.82 (m, 1H), 4.62-4.68 (m, 1H), 5.10 (s, 2H), 5.65 (s, 1H), 7.31-7.37 (m, 5H). MS (ES+): nz/z 304 [M+1].
[137] Part 2:
[138] Methyl (4-benzyloxycarbonylamino-l-nitromethylcyclohexyl)acetate (10): To a solution of methyl (4-benzyloxycarbonyl aminocyclohexylidene)acetate (303mg, 1.Ommo1) in nitromethane (5mL) was added 1,1,3,3-tetramethylguanidine (46 L).
The mixture was refluxed for 24h. The solvent was removed in vacuo and the residue was purified by silica gel chromatography (1% MeOH in CH2ClZ) to yield methyl (4-benzyloxycarbonylamino-l-nitromethylcyclo hexyl)acetate. 'H NMR (CDC13i 400MHz): 6 1.33-2.12 (m, 8H), 2.61 (s, 2H), 3.52-3.55 (m, 1H), 3.68 (s, 2H), 3.74 (s, 3H), 4.66-4.69 (m, 1H), 5.09 (s, 2H), 7.31-7.37 (m, 5H).
The mixture was refluxed for 24h. The solvent was removed in vacuo and the residue was purified by silica gel chromatography (1% MeOH in CH2ClZ) to yield methyl (4-benzyloxycarbonylamino-l-nitromethylcyclo hexyl)acetate. 'H NMR (CDC13i 400MHz): 6 1.33-2.12 (m, 8H), 2.61 (s, 2H), 3.52-3.55 (m, 1H), 3.68 (s, 2H), 3.74 (s, 3H), 4.66-4.69 (m, 1H), 5.09 (s, 2H), 7.31-7.37 (m, 5H).
[139] Part 3:
[140] 8-Amino-2-azaspiro[4.5]decan-3-one (12): Nitro compound methyl (4-benzyloxycarbonylamino-l-nitromethylcyclohexyl)acetate (130mg, 0.36mmol) was dissolved in EtOH (5mL) and Raney Ni (50% slurry in water, 3mL) was added under N2 atmosphere.
The resulting suspension was stirred at rt for 72h. The mixture was filtered through a Celite pad and solvent was removed in vacuo yield benzyl (3-oxo-2-azaspiro[4.5]dec-8-yl)carbamate (11) as an oil. Crude benzyl (3-oxo-2-azaspiro[4.5]dec-8-yl)carbamate was then dissolved in methanol (lOmL) and 10% Pd/C (100mg) was added. The solution was then deoxygenated and back filled with N2 atmosphere (repeated 2x). The solution was then degassed and back filled with Hz atmosphere (repeated 2x). The mixture was then stirred under H2 atmosphere at rt overnight. The mixture was filtered through a Celite pad and solvent was removed in vacuo yield crude 8-amino-2-azaspiro[4.5]decan-3-one, which was used directly in the coupling reaction without purification.
The resulting suspension was stirred at rt for 72h. The mixture was filtered through a Celite pad and solvent was removed in vacuo yield benzyl (3-oxo-2-azaspiro[4.5]dec-8-yl)carbamate (11) as an oil. Crude benzyl (3-oxo-2-azaspiro[4.5]dec-8-yl)carbamate was then dissolved in methanol (lOmL) and 10% Pd/C (100mg) was added. The solution was then deoxygenated and back filled with N2 atmosphere (repeated 2x). The solution was then degassed and back filled with Hz atmosphere (repeated 2x). The mixture was then stirred under H2 atmosphere at rt overnight. The mixture was filtered through a Celite pad and solvent was removed in vacuo yield crude 8-amino-2-azaspiro[4.5]decan-3-one, which was used directly in the coupling reaction without purification.
[141] EXAMPLE 10 N-(2-Methyl-3 -oxo-1,2-diazaspiro[4.5]dec-8-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide / \ N
H -N
E N _(/ ~ /
o N-N
H \
H -N
E N _(/ ~ /
o N-N
H \
[142] EXAMPLE 10 was prepared according to the procedure described for EXAMPLE 1 using 8-amino-2-methyl-1,2-diazaspiro[4.5]decan-3-one (compound 14 in the procedure below) instead of 1,4-dioxaspiro[4.5]dec-8-ylamine. MS (ES+) 450 [M+1].
O O
O O CH,NHNHZ O N- - HZ, Pd/C N_ N N
BnO~N OMe EtOH BnON H MeOH HZN H
H reflux H
O O
O O CH,NHNHZ O N- - HZ, Pd/C N_ N N
BnO~N OMe EtOH BnON H MeOH HZN H
H reflux H
[143] Part 1:
[144] Benzyl2-methyl-3-oxo-1,2-diazaspiro[4.5]dec-8-ylcarbamate (13): A
solution of inethylhydrazine (15.2mg, 0.33mmol) and ester 9(91mg, 0.30mmol) in EtOH
(lmL) was refluxed for 15h. The solvent was removed in vacuo and the residue was purified by silica gel chromatography (5% MeOH in CHzCIz) to yield benzyl 2-methyl-3-oxo-1,2-diazaspiro[4.5]dec-8-ylcarbamate. 1H NMR (CDC13, 400MHz): S 1.53-1.82 (m, 6H), 2.00-2.04 (m, 2H), 2.40 (s, 2H), 3.01 (s, 3H), 3.52-3.60 (m, 1H), 4.23 (brs, 1H), 4.62-4.69 (m, 1H), 5.09 (s, 2H), 7.30-7.44 (m, 5H). MS (ES+): rn/z 318 [M+1].
solution of inethylhydrazine (15.2mg, 0.33mmol) and ester 9(91mg, 0.30mmol) in EtOH
(lmL) was refluxed for 15h. The solvent was removed in vacuo and the residue was purified by silica gel chromatography (5% MeOH in CHzCIz) to yield benzyl 2-methyl-3-oxo-1,2-diazaspiro[4.5]dec-8-ylcarbamate. 1H NMR (CDC13, 400MHz): S 1.53-1.82 (m, 6H), 2.00-2.04 (m, 2H), 2.40 (s, 2H), 3.01 (s, 3H), 3.52-3.60 (m, 1H), 4.23 (brs, 1H), 4.62-4.69 (m, 1H), 5.09 (s, 2H), 7.30-7.44 (m, 5H). MS (ES+): rn/z 318 [M+1].
[145] Part 2:
[146] 8-Amino-2-methyl-1,2-diazaspiro[4.5]decan-3-one (14): To a solution of benzyl 2-methyl-3-oxo-1,2-diazaspiro[4.5]dec-8-ylcarbamate (74mg, 0.23mmol) in methanol (5mL) was added 10% Pd/C (150ing, 0.14mmol). The solution was then deoxygenated and back filled with N2 atmosphere (repeated 2x). The solution was then degassed and back filled with H2 atmosphere (repeated 2x). The mixture was then stirred under H2 atmosphere at rt overnight. The catalyst was removed by filtration through a Celite pad and the filtrate was concentrated in vacuo to yield crude 8-amino-2-methyl- 1,2-diazaspiro[4.5]
decan-3 -one, which was used directly in the next step without purification.
decan-3 -one, which was used directly in the next step without purification.
[147] EXAMPLE 11 trans-N-(2-Benzyl-3 -oxo-l,2-diazaspiro [4.5] dec-8-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide N
H
N H
ES~\ N-t=:~_ H
, N
O N
O
H
N H
ES~\ N-t=:~_ H
, N
O N
O
[148] EXAMPLE 11 was prepared according to the procedure described for EXAMPLE 1 using 8-amino-2-benzyl-1,2-diazaspiro[4.5]decan-3-one (prepared according the procedure described above for compound 14 using benzylhydrazine instead of methylhydrazine) instead of 1,4-dioxaspiro[4.5]dec-8-ylamine. MS (ES+) 526 [M+1].
[149] COMPOUND 2 cis-N-(2-B enzyl-3 -oxo-1,2-diazaspiro [4.5] dec-8-yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide H
N
N H
S
o HN-N O
N
N H
S
o HN-N O
[150] COMPOUND 2 was prepared according to the procedure described for EXAMPLE 1 using 8-amino-2-benzyl-1,2-diazaspiro[4.5]decan-3-one (prepared according the procedure described above for compound 14 using benzylhydrazine instead of methylhydrazine) instead of 1,4-dioxaspiro[4.5]dec-8-ylamine. MS (ES+) 526 [M+1].
[151] COMPOUND 3 N-( 3-B enzyl-2,4-dioxo-1, 3-diazaspiro [4.5 ] dec- 8-yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide o ~N4 S ~~N
NH
~
/ -N
NH
~
/ -N
[152] COMPOUND 3 was prepared according to the procedure described for EXAMPLE 1 using 8-amino-3-benzyl-1,3-diazaspiro[4.5]decane-2,4-dione (compound 17 in the procedure below) instead of 1,4-dioxaspiro[4.5]dec-8-ylamine. MS (ES+) 435 [M+1].
0 0 H 0 BnBr Bn0-/< KCN, (NH4)ZC03 Bn0-J N- f K2C03, DMF
H~0 EtOH/H,0 HNH
reflux 0 O
BnO~ N- f0/ I HZ,/Pd-C N /
I
H H~N N ~ _C:X;
MeOH
0 0 H 0 BnBr Bn0-/< KCN, (NH4)ZC03 Bn0-J N- f K2C03, DMF
H~0 EtOH/H,0 HNH
reflux 0 O
BnO~ N- f0/ I HZ,/Pd-C N /
I
H H~N N ~ _C:X;
MeOH
[153] Part 1:
[154] Benzy12,4-dioxo-1,3-diazaspiro[4.5]dec-8-ylcarbamate (15): A mixture of lcetone 2 (800mg, 3.2mmo1), KCN (314mg, 4.8nnnol), and (NH4)2CO3 (930mg, 9.7mmo1) in a 1:1 solution of ethanol/water (20mL) was heated to reflux. After 18h the reaction was cooled to rt and the solvent was reduced ifz vacuo until precipitation occurred. The solution was filtered and benzy12,4-dioxo-1,3-diazaspiro[4.5]dec-8-ylcarbamate was collected as a white solid. 'H NMR (400MHz/CDC13): S 1.22-1.40 (m,2H), 1.76-1.80 (m, 2H), 1.90-2.2 (m, 4H), 3.53-3.65 (m, 1H), 5.10 (s, 2H), 7.25-7.40 (m, 5H). MS (ES+): 318[M+1].
[155] Part 2:
[156] Benzyl3-benzyl-2,4-dioxo-1,3-diazaspiro[4.5]dec-8-ylcarbamate (16): A
mixture of benzyl 2,4-dioxo-1,3-diazaspiro[4.5]dec-8-ylcarbamate (80mg, 0.25nunol), benzyl bromide (33 L, 0.28mmol), and K2CO3 (34.6mg, 0.25mmo1) in DMF was stirred at rt for 24h.
The reaction mixture was then partitioned between ethyl acetate and water. The organic layer was concentrated in vacuo and the residue was washed with a minimum amount of MeOH
and ethyl acetate to give pure benzyl 3 -benzyl-2,4-dioxo- 1,3 -diazaspiro [4.5] dec-8 -ylcarbaniate. 1H NMR (400MHz/ DC13): 8 1.23-1.29 (m, 2H), 1.67 (d, J= 13.7 Hz, 2H), 1.99 (t, J= 14.8 Hz, 2H), 2.12 (d, J= 11.6 Hz, 2H), 3.54-3.67 (m, 1H), 4.64 (s, 3H), 5.10 (s, 2H), 6.49 (s, 1H), 7.31-7.35 (m, 10H). MS (ES+): 408 [M+1].
mixture of benzyl 2,4-dioxo-1,3-diazaspiro[4.5]dec-8-ylcarbamate (80mg, 0.25nunol), benzyl bromide (33 L, 0.28mmol), and K2CO3 (34.6mg, 0.25mmo1) in DMF was stirred at rt for 24h.
The reaction mixture was then partitioned between ethyl acetate and water. The organic layer was concentrated in vacuo and the residue was washed with a minimum amount of MeOH
and ethyl acetate to give pure benzyl 3 -benzyl-2,4-dioxo- 1,3 -diazaspiro [4.5] dec-8 -ylcarbaniate. 1H NMR (400MHz/ DC13): 8 1.23-1.29 (m, 2H), 1.67 (d, J= 13.7 Hz, 2H), 1.99 (t, J= 14.8 Hz, 2H), 2.12 (d, J= 11.6 Hz, 2H), 3.54-3.67 (m, 1H), 4.64 (s, 3H), 5.10 (s, 2H), 6.49 (s, 1H), 7.31-7.35 (m, 10H). MS (ES+): 408 [M+1].
[157] Part 3:
[158] 8-Amino-3-benzyl-1,3-diazaspiro[4.5]decane-2,4-dione (17): Benzyl 3-benzyl-2,4-dioxo-1,3-diazaspiro[4.5]dec-8-ylcarbamate was dissolved in MeOH
(13mg,' 0.032mmo1) and 10% Pd/C (10mg, 9 mo1) was added. The solution was then deoxygenated and back filled with N2 atmosphere (repeated 2x). The solution was then degassed and back filled with H2 atmosphere (repeated 2x). The mixture was then stirred under H2 atmosphere at rt overnight. The mixture was filtered through a Celite pad and solvent was removed in vacuo yield pure 8-amino-3-benzyl-1,3-diazaspiro[4.5]decane-2,4-dione. MS
(ES+): 274 [M+1].
(13mg,' 0.032mmo1) and 10% Pd/C (10mg, 9 mo1) was added. The solution was then deoxygenated and back filled with N2 atmosphere (repeated 2x). The solution was then degassed and back filled with H2 atmosphere (repeated 2x). The mixture was then stirred under H2 atmosphere at rt overnight. The mixture was filtered through a Celite pad and solvent was removed in vacuo yield pure 8-amino-3-benzyl-1,3-diazaspiro[4.5]decane-2,4-dione. MS
(ES+): 274 [M+1].
[159] EXAMPLE 12 trans-N-(2,4-Dioxo-1,3 -diazaspiro [4.5] dec-8-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide: MS (ES+) 450 [M+1]
H -N
N H
O N
O=:~ ~ O
H
H -N
N H
O N
O=:~ ~ O
H
[160] EXAMPLE 12 was prepared using 3-[(Quinolin-4-ylmethyl)amino]thiophene-2-carboxylic acid hydrochloride (19, EXAMPLE 1) and the appropriate amine (prepared according to the procedure described above for omitting the allcylation step of part 2), according to the procedure described for EXAMPLE
1.
1.
[161] The following analogues were prepared using 3-[(Quinolin-4-ylmethyl)amino]thiophene-2-carboxylic acid hydrochloride (19, EXAMPLE 1) and the appropriate amine (prepared according to the procedure described above for using the appropriate alkylating agent in part 2), according to the procedure described for EXAMPLE 1.
[162] COMPOUND 4 N-(2,4-Dioxo-1,3 -diazaspiro [4.5] dec-8-yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide: MS (ES+) 450 [M+l]
O N
O ~ a~0 H H
H
N
O N
O ~ a~0 H H
H
N
[163] EXAMPLE 13 N-(3 -Methyl-2,4-dioxo-1, 3 -diazaspiro [4. 5 ] dec-8 -yl) -3 - [ (quinolin-4-ylmethyl)amino]thiophene-2-carboxamide: MS (ES+) 464 [M+1]
o O N
S ~O
H H
NH
N
o O N
S ~O
H H
NH
N
[164] EXAMPLE 14 N- [3 -(3 -Methylbutyl) -2,4-dioxo-1, 3 -di azaspiro [4.5 ] dec-8 -yl] -3 - [
(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide: MS (ES+) 520 [M+l]
O )-~c O
H
NH
~
/ -N
(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide: MS (ES+) 520 [M+l]
O )-~c O
H
NH
~
/ -N
[165] COMPOUND 5 N-[3-(3-Methylbutyl)-2,4-dioxo-1,3-diazaspiro [4.5]dec-8-yl]-4-methyl-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide O
O SH ~N%
NH
N
O SH ~N%
NH
N
[166] COMPOUND 5 was prepared using 3-[(Quinolin-4-ylmethyl)amino]thiophene-2-carboxylic acid hydrochloride (prepared according to the procedure described for EXAMPLE 1 using 3-amino-4-methyl-thiophene-2-carboxylic acid methyl ester instead of 3-amino-thiophene-2-carboxylic acid methyl ester) and 8-amino-3-(3-methylbutyl)-1,3-diazaspiro[4.5]decane-2,4-dione (prepared according to the procedure described for COMPOUND 3 using the appropriate alkylating agent in part 2), according to the procedure described for EXAMPLE 1. MS (ES+) 438 [M+1].
[167] EXAMPLE 15 N-(1'-Methyl-2-oxo-1,2-dihydrospiro [indole-3,4'-piperidin] -5 -yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide / \
_ DN H N N
rS 1 N O
O 1 ~ H
_ DN H N N
rS 1 N O
O 1 ~ H
[168] EXAMPLE 15 was prepared by the following procedure:
H I. NaHMDS, THF
H2N I~ O II
Boc2O, Et3N kOUN I N O -78 C
~ N THF O
H H ii. CI~~N~~CI
21 =HCI
-78 C->rt N N
UN 4 N HCI _ IOI I j O dioxane HzN SN
O
Np H H
H o N N
NH2 1. NaOH, H2O, N - MeOH _ ~ N
\ O~ =HCI
S Et3SiH 2. HCI
O TFA/DCM r \ O~ C \ OH
S S
~ O 0 N 18 % 19 H2N~~\i~ ~
N - N /
N H _ N
EDC, HOAt, EtNPr'2 /\ N O
CHZCIa, rt, 18 h S N
H I. NaHMDS, THF
H2N I~ O II
Boc2O, Et3N kOUN I N O -78 C
~ N THF O
H H ii. CI~~N~~CI
21 =HCI
-78 C->rt N N
UN 4 N HCI _ IOI I j O dioxane HzN SN
O
Np H H
H o N N
NH2 1. NaOH, H2O, N - MeOH _ ~ N
\ O~ =HCI
S Et3SiH 2. HCI
O TFA/DCM r \ O~ C \ OH
S S
~ O 0 N 18 % 19 H2N~~\i~ ~
N - N /
N H _ N
EDC, HOAt, EtNPr'2 /\ N O
CHZCIa, rt, 18 h S N
[169] Part 1:
[170] tert-Butyl 2-oxo-2,3-dihydro-lH-indol-5-ylcarbamate (21): To a mixture of 5-amino-1,3-dihydro-2H-indol-2-one (148mg, 1.Ommo1), di-tert-butyl dicarbonate (262mg, 1.2mmo1), and Et3N (279 L, 2.0mmo1) was added dry THF (5mL). The suspension was then stirred at rt for 24h. The reaction was concentrated in vacuo to yield tert-butyl 2-oxo-2,3-dihydro-lH-indol-5-ylcarbamate as a brown solid. 'H NMR (CDC13, 400MHz): 8 1.52 (s, 9 H), 3.52 (s, 2 H), 6.38 (brs, 1H), 6.76 (d, J= 8.0 Hz, 1H), 7.07 (dd, J= 2.4, 8.4 Hz, 1H), 7.26 (d, J= 2.4 Hz, 1H), 7.42 (brs, 1H). MS (ES+): na/z 249 [M+1].
[171] Part 2:
[172] tert-Butyl 1'-methyl-2-oxo-1,2-dihydrospiro [indole-3,4'-piperidin]-5-ylcarbamate (22): A solution of tert-butyl2-oxo-2,3-dihydro-lH-indol-5-ylcarbamate (248mg, 1.0mmo1) in THF (3mL) was cooled to -78 C and a 1M solution of sodium hexamethyldisilazide in THF (6mL, 6.0mmo1) was added drop-wise. After stirring at -78 C
for 30min, N,N-bis(2-chloroethyl)-N-methylamine hydrochloride (193mg, 1.0mmol) was added. The reaction mixture was stirred at -78 C for 30min and then at rt for 2 days. The reaction was quenched with water (2mL) and the mixture was extracted with EtOAc (3x50mL). The organic extracts were combined, dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (10% MeOH
in dichloromethane) to yield tert-butyl 1'-methyl-2-oxo-1,2-dihydrospiro[indole-3,4'-piperidin]-5-ylcarbamate. 'H NMR (CDC13, 400MHz): 8 1.51 (s, 9H), 1.88-1.93 (m, 2H), 2.52-2.62 (m, 2H), 2.72 (s, 3H), 3.14-3.17 (m, 2H), 3.44-3.50 (m, 2H), 6.64 (s, 1H), 6.84 (d, J= 8.4 Hz, 1H), 7.47 (brs, 1H), 7.83 (brs, 1H). MS (ES+): nz/z 332 [M+1].
for 30min, N,N-bis(2-chloroethyl)-N-methylamine hydrochloride (193mg, 1.0mmol) was added. The reaction mixture was stirred at -78 C for 30min and then at rt for 2 days. The reaction was quenched with water (2mL) and the mixture was extracted with EtOAc (3x50mL). The organic extracts were combined, dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (10% MeOH
in dichloromethane) to yield tert-butyl 1'-methyl-2-oxo-1,2-dihydrospiro[indole-3,4'-piperidin]-5-ylcarbamate. 'H NMR (CDC13, 400MHz): 8 1.51 (s, 9H), 1.88-1.93 (m, 2H), 2.52-2.62 (m, 2H), 2.72 (s, 3H), 3.14-3.17 (m, 2H), 3.44-3.50 (m, 2H), 6.64 (s, 1H), 6.84 (d, J= 8.4 Hz, 1H), 7.47 (brs, 1H), 7.83 (brs, 1H). MS (ES+): nz/z 332 [M+1].
[173] Part 3:
[174] 5-Amino-1'-methylspiro[indole-3,4'-piperidin]-2(1I3)-one (23): To a solution of tert-butyl 1'-methyl-2-oxo-1,2-dihydrospiro[indole-3,4'-piperidin]-5-ylcarbamate (50mg, 0.15mmo1) in dioxane (2mL) was added 4N HCl (lmL). The mixture was stirred at rt for 16h. The reaction was concentrated in vacuo and the residue was dissolved in dichloromethane (IOmL). Saturated NaHCO3 (5mL) was added and the mixture was stirred at rt for lh. The organic phase was removed and the aqueous phase was extracted with dichloromethane (2x l OmL). The organic extracts were combined, dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (15% MeOH in dichloromethane) to afford 5-amino-1'-methylspiro[indole-3,4'-piperidin]-2(1F1)-one. 'H NMR (CDC13i 400MHz): b 1.88-1.93 (m, 2H), 2.70-2.90 (m, 5H), 3.23-3.32 (m, 2H), 3.58-3.70 (m, 2H), 6.55 (d, J= 8.0 Hz, 1H), 6.67 (d, J= 8.0 Hz, 1H), 6.79 (s, 1H), 7.13 (brs, 1H). MS (ES+): rn/z 232 [M+1].
[175] Part 4:
[176] Methyl3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxylate (18): A
mixture of 3-amino-thiophene-2-carboxylic acid methyl ester (5g, 31.8mmo1) and quinoline-carboxaldehyde (5.25g, 33.4nunol) in TFA/CH2C12 (75mL, 75mL) was heated at 50 C for 3.5h. The solution was cooled in an ice bath and triethylsilane (10.2mL, 63.6mmol) was added drop-wise over 5min. The reaction mixture was stirred at 50 C for 3.5h, cooled to rt, and 500 mL of CH2C12 was added. The reaction mixture was basified with l ON NaOH (pH
6-7) followed by sat. NaHCO3 (pH 8). The CH2C121ayer was separated and the aqueous layer was extracted with CH2C12 (2xlOOmL). The organic extracts were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to yield the crude product, which was triturated with hexane to give pure methyl 3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxylate as white solid. MS (ES): nz/z 298.55 (100) [MH+];
'H-NMR (400MHz/CDC13): 6 3.87 (s, 3H), 5.00 (d, J= 4.0 Hz, 2H), 6.48 (d, J=
5.6 Hz, 1H), 7.30 (d, J= 5.6 Hz, 1H), 7.36 (m, 1H), 7.41 (d, J= 4.4 Hz, 111), 7.62 (t, J=
8.0 Hz, 1H), 7.76 (t, J= 9.6 Hz, 1H), 8.01 (d, J= 8.0 Hz, 1H), 8.17 (d, J= 8.4 Hz, 1H), 8.86 (d, J= 4.4 Hz, 1H).
mixture of 3-amino-thiophene-2-carboxylic acid methyl ester (5g, 31.8mmo1) and quinoline-carboxaldehyde (5.25g, 33.4nunol) in TFA/CH2C12 (75mL, 75mL) was heated at 50 C for 3.5h. The solution was cooled in an ice bath and triethylsilane (10.2mL, 63.6mmol) was added drop-wise over 5min. The reaction mixture was stirred at 50 C for 3.5h, cooled to rt, and 500 mL of CH2C12 was added. The reaction mixture was basified with l ON NaOH (pH
6-7) followed by sat. NaHCO3 (pH 8). The CH2C121ayer was separated and the aqueous layer was extracted with CH2C12 (2xlOOmL). The organic extracts were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to yield the crude product, which was triturated with hexane to give pure methyl 3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxylate as white solid. MS (ES): nz/z 298.55 (100) [MH+];
'H-NMR (400MHz/CDC13): 6 3.87 (s, 3H), 5.00 (d, J= 4.0 Hz, 2H), 6.48 (d, J=
5.6 Hz, 1H), 7.30 (d, J= 5.6 Hz, 1H), 7.36 (m, 1H), 7.41 (d, J= 4.4 Hz, 111), 7.62 (t, J=
8.0 Hz, 1H), 7.76 (t, J= 9.6 Hz, 1H), 8.01 (d, J= 8.0 Hz, 1H), 8.17 (d, J= 8.4 Hz, 1H), 8.86 (d, J= 4.4 Hz, 1H).
[177] Part 5:
[178] 3-[(Quinolin-4-ylmethyl)amino]thiophene-2-carboxylic acid hydrochloride (19): To a suspension of 3-[(quinolin-4-ylmethyl)-amino]-thiophene-2-carboxylic acid methyl ester (5.OOg, 16.8mmo1) in a mixture of H20 (20mL) and MeOH
(250mI.,) was added solid NaOH (6.7g, 167.5mmo1). The reaction mixture was stirred at reflux for 5h. The organic solvent was evaporated under reduced pressure and water (60mL) was added to dissolve the residue. The aqueous solution was washed with ethyl acetate (50mL) and then acidified with 1N HCl to pH 5-6. 3-[(Quinolin-4-ylmethyl)amino]thiophene-2-carboxylic acid hydrochloride precipitated from solution and was collected by filtration. IHNMR (400MHz/DMSO-d6): 8 5.07 (s, 2H), 6.71 (d, J= 4.0 Hz, 1H), 7.36 (d, J= 4.0 Hz, 1H), 7.43 (m, 1H), 7.58 (d, J= 4.0 Hz, 1H), 7.67 (t, J= 8.4 Hz, 1H), 7.80 (t, J= 7.2 Hz, 1H), 8.06 (d, J= 8.4 Hz, 1H), 8.22 (d, J= 8.4 Hz, 1H), 8.83 (d, J= 3.6 Hz, 1H), 12.30 (s, 1H). MS (ES+): 285[MH+].
(250mI.,) was added solid NaOH (6.7g, 167.5mmo1). The reaction mixture was stirred at reflux for 5h. The organic solvent was evaporated under reduced pressure and water (60mL) was added to dissolve the residue. The aqueous solution was washed with ethyl acetate (50mL) and then acidified with 1N HCl to pH 5-6. 3-[(Quinolin-4-ylmethyl)amino]thiophene-2-carboxylic acid hydrochloride precipitated from solution and was collected by filtration. IHNMR (400MHz/DMSO-d6): 8 5.07 (s, 2H), 6.71 (d, J= 4.0 Hz, 1H), 7.36 (d, J= 4.0 Hz, 1H), 7.43 (m, 1H), 7.58 (d, J= 4.0 Hz, 1H), 7.67 (t, J= 8.4 Hz, 1H), 7.80 (t, J= 7.2 Hz, 1H), 8.06 (d, J= 8.4 Hz, 1H), 8.22 (d, J= 8.4 Hz, 1H), 8.83 (d, J= 3.6 Hz, 1H), 12.30 (s, 1H). MS (ES+): 285[MH+].
[179] Part 6:
[180] N-(1'-Methyl-2-oxo-1,2-dihydrospiro [indole-3,4'-piperidin]-5-y1)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide (24): To a suspension of 3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxylic acid hydrochloride (45mg, 0.14mmo1) and 5-amino-1'-methylspiro[indole-3,4'-piperidin]-2(1H)-one (25mg, 0.11mmo1) in dichloromethane (2mL) was added EDC (29mg, 0.15mmo1), HOAt (0.5M solution in DMF, 60 L, 0.03mmo1) and i-Pr2NEt (0.13mL, 0.76mmol). The mixture was stirred at rt for 18h.
The reaction was then concentrated in vacuo and the residue was purified by silica gel chromatography (5-10% MeOH in dichloro-methane) to afford EXAMPLE 15. 'H NMR
(CDC13, 400MHz): 8 1.96-2.05 (m, 4H), 2.45 (s, 3H), 2.68-2.73 (m, 2H), 2.90-2.96 (m, 2H), 5.00 (d, J= 6.0 Hz, 2H), 6.56 (d, J= 5.6 Hz, 1H), 6.85 (d, J= 8.4 Hz, 1H), 7.17 (s, 1H), 7.23 (d, J= 5.2 Hz, 1H), 7.33 (dd, J= 2.0, 8.4 Hz, 1H), 7.46 (d, J= 4.8 Hz, 1H), 7.59-7.64 (m, 2H), 7.76 (dd, J= 0.8, 8.0 Hz, 1H), 8.02-8.05 (m, 2H), 8.09 (brs, 1H), 8.17 (d, J= 8.0 Hz, 1H), 8.86 (d, J= 4.4 Hz, 1H). MS (ES+): rn/z 498 [M+1].
The reaction was then concentrated in vacuo and the residue was purified by silica gel chromatography (5-10% MeOH in dichloro-methane) to afford EXAMPLE 15. 'H NMR
(CDC13, 400MHz): 8 1.96-2.05 (m, 4H), 2.45 (s, 3H), 2.68-2.73 (m, 2H), 2.90-2.96 (m, 2H), 5.00 (d, J= 6.0 Hz, 2H), 6.56 (d, J= 5.6 Hz, 1H), 6.85 (d, J= 8.4 Hz, 1H), 7.17 (s, 1H), 7.23 (d, J= 5.2 Hz, 1H), 7.33 (dd, J= 2.0, 8.4 Hz, 1H), 7.46 (d, J= 4.8 Hz, 1H), 7.59-7.64 (m, 2H), 7.76 (dd, J= 0.8, 8.0 Hz, 1H), 8.02-8.05 (m, 2H), 8.09 (brs, 1H), 8.17 (d, J= 8.0 Hz, 1H), 8.86 (d, J= 4.4 Hz, 1H). MS (ES+): rn/z 498 [M+1].
[181] EXAMPLE 16 N-(2-Oxo-1, 2, 2', 3', 5', 6'-hexahydro spiro [indol e-3 ,4'-pyran] -5 -yl) -3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide N
H O
N
C ~ N O N S 0 1 ~ H
H O
N
C ~ N O N S 0 1 ~ H
[182] The following analogues were prepared according to the procedure described above for EXAMPLE 15, using diethylene glycol di(p-toluenesulfonate) instead of N,N-bis(2-chloroethyl)-N-methylamine hydrochloride. MS (ES+) 485 [M+l].
[183] COMPOUND 6 Benzyl5-{ [(3-[(quinolin-4-ylmethyl)amino]thien-2-yl)carbonyl]amino}-2-oxo-1,2-dihydro-1'H-spiro [indole-3,4'-piperidine] -1'-carboxylate ~I
~
N 0y 0 ~
H ~ N
N
/~N
S N
O H
~
N 0y 0 ~
H ~ N
N
/~N
S N
O H
[184] COMPOUND 6 was prepared according to the procedure described for EXAMPLE 15 using benzyl5-amino-l,2-dihydro-1'H-spiro[indole-3,4'-piperidine]-1'-carboxylate (compound 26 in the procedure below) instead of 5-amino-1'-methylspiro[indole-3,4'-piperidin]-2(lM-one. MS (ES+) 604 [M+1].
O H
NHNHZ O ~
1. TFA, DCM N
N + 40 C
O 2. NaBH4 02N NOZ N
H
O
N O
SnC12=HZO
EtOH, reflux H2N C N
H
O H
NHNHZ O ~
1. TFA, DCM N
N + 40 C
O 2. NaBH4 02N NOZ N
H
O
N O
SnC12=HZO
EtOH, reflux H2N C N
H
[185] Part 1:
[186] Benzyl5-nitro-1,2-dihydro-1'H-spiro [indole-3,4'-piperidine]-1'-carboxylate (25): To a solution of 4-nitrophenylhydrazine (842mg, 5.5mmo1) and TFA
(5mL) in dichloromethane (20mL) was added benzyl 4-formylpiperidine- 1 -carboxylate (1.24g, 5.Ommol). The mixture was stirred at 40 C for 16h. The reaction was then cooled to rt and NaBH4 (378mg, 10.Onunol) was added portion-wise over 30min. The mixture was then stirred for an additiona130min and then washed with 10% NH40H (100 mL). The organic phase was dried over MgSO4, filtered, and concentrated in vacuo. The crude product was purified by silica gel chromatography (5% MeOH in dichloromethane) to yield benzyl5-nitro-1,2-dihydro-1'H-spiro[indole-3,4'-piperidine]-1'-carboxylate. 'H NMR
(CDC13, 400MHz): S 1.70-1.80 (m, 2H), 1.80-1.95 (m, 2H), 2.92-3.01 (m, 2H), 3.67 (s, 2H), 4.13-4.28 (m, 2H), 4.48 (s, 1H), 5.18 (s, 2H), 6.52 (dd, J= 2.0, 8.8 Hz, 1H), 7.34-7.40 (m, 5H), 7.89 (d, J= 2.0 Hz, 1H), 8.04 (dt, J= 2.4, 6.4 Hz, 1H). MS (ES+): rn/z 368 [M+1].
(5mL) in dichloromethane (20mL) was added benzyl 4-formylpiperidine- 1 -carboxylate (1.24g, 5.Ommol). The mixture was stirred at 40 C for 16h. The reaction was then cooled to rt and NaBH4 (378mg, 10.Onunol) was added portion-wise over 30min. The mixture was then stirred for an additiona130min and then washed with 10% NH40H (100 mL). The organic phase was dried over MgSO4, filtered, and concentrated in vacuo. The crude product was purified by silica gel chromatography (5% MeOH in dichloromethane) to yield benzyl5-nitro-1,2-dihydro-1'H-spiro[indole-3,4'-piperidine]-1'-carboxylate. 'H NMR
(CDC13, 400MHz): S 1.70-1.80 (m, 2H), 1.80-1.95 (m, 2H), 2.92-3.01 (m, 2H), 3.67 (s, 2H), 4.13-4.28 (m, 2H), 4.48 (s, 1H), 5.18 (s, 2H), 6.52 (dd, J= 2.0, 8.8 Hz, 1H), 7.34-7.40 (m, 5H), 7.89 (d, J= 2.0 Hz, 1H), 8.04 (dt, J= 2.4, 6.4 Hz, 1H). MS (ES+): rn/z 368 [M+1].
[187] Part 2:
[188] Benzyl5-amino-1,2-dihydro-1'H-spiro[indole-3,4'-piperidine]-1'-carboxylate (26): A suspension of benzyl5-nitro-1,2-dihydro-1'H-spiro[indole-3,4'-piperidine]-1'-carboxylate (735mg, 2.0mmol) and SnC12.2H20 (4.51 g, 20.0 mmol) in EtOH
(30 mL) was stirred at reflux for 6 h. After cooling to room temperature, sat.
NaHCO3 (aq.) was added until pH 9-10. The resulting solids were removed by filtration through a Celite pad and the filtrate was concentrated in vacuo. The residue was redissolved in dichloromethane and the aqueous phase was separated. The organic phase was dried over MgSO4, filtered, and concentrated in vacuo to yield benzyl5-amino-l,2-dihydro-1'H-spiro[indole-3,4'-piperidine]-1'-carboxylate. MS (ES+): m/z 338 [M+1].
(30 mL) was stirred at reflux for 6 h. After cooling to room temperature, sat.
NaHCO3 (aq.) was added until pH 9-10. The resulting solids were removed by filtration through a Celite pad and the filtrate was concentrated in vacuo. The residue was redissolved in dichloromethane and the aqueous phase was separated. The organic phase was dried over MgSO4, filtered, and concentrated in vacuo to yield benzyl5-amino-l,2-dihydro-1'H-spiro[indole-3,4'-piperidine]-1'-carboxylate. MS (ES+): m/z 338 [M+1].
[189] EXAMPLE 17 N-(2'-Oxo-1',2'-dihydrospiro [ 1,3-dioxolane-2,3'-indol]-5'-yl)-3 -[(quinolin-ylmethyl)amino]thiophene-2-carboxamide N
H - /~
N O O
g 0 / H
H - /~
N O O
g 0 / H
[190] EXAMPLE 17 was prepared according to the procedure described for EXAMPLE 15 using 5'-aminospiro[1,3-dioxolane-2,3'-indol]-2'(1'FI)-one (compound 28 in the procedure below) instead of 5-amino-1'-methylspiro[indole-3,4'-piperidin]-2(lH)-one.
MS (ES+) 473 [M+1].
0 OZN_r\/~ p-TsOH=H2O OZN \O 0 '~ , N 0 + HO OH toluene, 120 C (, O
H N
H
Ha1 Pd/C LiAIH4, THF n MeOH HzN O O reflux _ HZN O O
~
N
H H
MS (ES+) 473 [M+1].
0 OZN_r\/~ p-TsOH=H2O OZN \O 0 '~ , N 0 + HO OH toluene, 120 C (, O
H N
H
Ha1 Pd/C LiAIH4, THF n MeOH HzN O O reflux _ HZN O O
~
N
H H
[191] Part 1:
[192] 5'-Nitrospiro[1,3-dioxolane-2,3'-indol]-2'(1'H)-one (27): To a suspension of 5-nitro-lH-indole-2,3-dione (384 mg, 2.0 mmol) and ethylene glycol (248 mg, 4.0 mmol) in toluene was addedp-TsOH.H20 (19 mg, 0.1 mmol). The mixture was refluxed for 18 h with a Dean-Stark trap and the water produced was removed during the reaction.
The reaction was then cooled to room temperature and the desired 5'-nitrospiro[1,3-dioxolane-2,3'-indol]-2'(1'H)-one precipitated out of solution and was collected by filtration. 'H NMR
(CDC13, 400 MHz): S 4.37-4.41 (m, 2H), 4.56-4.60 (m, 2H), 6.95 (d, J= 8.4 Hz, 1H), 7.70 (brs, 1H), 8.27 (d, J= 2.0 Hz, 1H), 8.30 (dd, J= 2.0, 8.4 Hz, 1H).
The reaction was then cooled to room temperature and the desired 5'-nitrospiro[1,3-dioxolane-2,3'-indol]-2'(1'H)-one precipitated out of solution and was collected by filtration. 'H NMR
(CDC13, 400 MHz): S 4.37-4.41 (m, 2H), 4.56-4.60 (m, 2H), 6.95 (d, J= 8.4 Hz, 1H), 7.70 (brs, 1H), 8.27 (d, J= 2.0 Hz, 1H), 8.30 (dd, J= 2.0, 8.4 Hz, 1H).
[193] Part 2:
[194] 5'-Aminospiro[1,3-dioxolane-2,3'-indol]-2'(1'H)-one (28): To a suspension of 5'-nitrospiro[1,3-dioxolane-2,3'-indol]-2'(1'R)-one (379mg, 1.6mmo1) was added 10% Pd/C
(50mg, 0.046mmo1). The solution was then deoxygenated and back filled with N2 atmosphere (repeated 2x). The solution was then degassed and back filled with H2 atmosphere (repeated 2x). The mixture was then stirred under H2 atmosphere at rt overnight. The catalyst was removed by filtration through a Celite pad and the filtrate was concentrated iia vacuo to yield 5'-aminospiro[1,3-dioxolane-2,3'-indol]-2'(1'H)-one. MS (ES+): m/z 207 [M+1].
(50mg, 0.046mmo1). The solution was then deoxygenated and back filled with N2 atmosphere (repeated 2x). The solution was then degassed and back filled with H2 atmosphere (repeated 2x). The mixture was then stirred under H2 atmosphere at rt overnight. The catalyst was removed by filtration through a Celite pad and the filtrate was concentrated iia vacuo to yield 5'-aminospiro[1,3-dioxolane-2,3'-indol]-2'(1'H)-one. MS (ES+): m/z 207 [M+1].
[195] Part 3:
[196] 1',2'-Dihydrospiro[1,3-dioxolane-2,3'-indol]-5'-amine (29): To a suspension of LiAlH4 (100mg, 2.5mmol) in THF (lOmL) was added 5'-aminospiro [1,3-dioxolane-2,3'-indol]-2'(1'H)-one (135mg, 0.7mmol). The mixture was stirred at rt for 30min and at reflux for 3h. After cooling to rt, water (1mL) was added drop-wise to quench the reaction. The reaction was concentrated in vacuo and the residue was purified by silica gel chromatography (5% MeOH in CH2C12) to yield 1',2'-dihydrospiro[1,3-dioxolane-2,3'-indol]-5'-amine. 'H NMR (CD3OD, 400MHz): 8 3.55-3.58 (m, 2H), 3.88 (t, J= 4.4 Hz, 2H), 4.04 (t, J= 4.4 Hz, 2H), 6.69 (dd, J= 2.0, 8.8 Hz, 1H), 6.75 (s, 1H), 6.07 (d, J=
8.8 Hz, 1H). MS
(ES+): m/z 193 [M+1].
8.8 Hz, 1H). MS
(ES+): m/z 193 [M+1].
[197] EXAMPLE 18 N-1',2'-Dihydrospiro[ 1,3-dioxolane-2,3'-indol]-5'-yl-3-[(pyridin-4-ylmethyl)amino]thiophene-2-carboxamide / ~ N
_ ~
H -N O S
I N,( S 0 \~ / H
_ ~
H -N O S
I N,( S 0 \~ / H
[198] EXAMPLE 18 was prepared according to the procedure described for EXAMPLE 15 using 1',2'-dihydrospiro[1,3-dioxolane-2,3'-indol]-5'-amine (compound 29 in the procedure above) instead of 5-amino-1'-methylspiro[indole-3,4'-piperidin]-2(1H)-one.
MS (ES+) 459 [M+1].
MS (ES+) 459 [M+1].
[199] EXAMPLE 19 N-(2'-Oxo-1',2'-dihydrospiro[ 1,3-dithiolane-2,3'-indol]-5'-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide N
N S S
S N_~'\J~i!~O
O 1 ~ -38-[200] EXAMPLE 19 was prepared according to the procedure described for EXAMPLE 18 using ethylene thioglycol instead of ethylene glycol. MS (ES+) 505 [M+1].
[2011 EXAMPLE 20 N-(1,3-Dimethyl-2'-oxo-1',2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide / \ N
H
N N -N N~
C ~
O O
S 1 ~ H
[202] EXAMPLE 20 was prepared according to the procedure described for EXAMPLE 18 using N,N'-dimethylethylenediamine instead of ethylene glycol. MS
(ES+) 499 [M+1].
[203] EXAMPLE 21 N-(2'-Oxo-1',2'-dihydrospiro[ 1,3-dioxane-2,3'-indol]-5'-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide S / \ DN
_ H N ci300 H
[204] EXAMPLE 21 was prepared according to the procedure described for EXAMPLE 18 using propylene glycol instead of ethylene glycol. MS (ES+) 487 [M+1]
[205] EXAMPLE 22 4-Methyl-N-(2'-oxo-1', 2'-dihydro spiro [ 1, 3-dioxolane-2, 3'-indol] -5'-yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide / \ N
N O O
N ~ O
S / N
O H
[206] EXAMPLE 22 was prepared according to the procedure described above for EXAMPLE 17 using 3-amino-4-methyl-thiophene-2-carboxylic acid methyl ester instead of 3-amino-thiophene-2-carboxylic acid methyl ester. MS (ES+)487 [M+1].
[207] EXAMPLE 23 4-Methyl-N-(2'-oxo-l',2'-dihydrospiro[1,3-dithiolane-2,3'-indol]-5'-yl) -3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide / \ N
H
N S S
N O
S N
O H
[208] EXAMPLE 23 was prepared according to the procedure described above for EXAMPLE 19 using 3-amino-4-methyl-thiophene-2-carboxylic acid methyl ester instead of 3-amino-thiophene-2-carboxylic acid methyl ester. MS (ES+)519 [M+1].
[209] EXAMPLE 24 N-(1,3-Dimethyl-2'-oxo-l',2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)-4-methyl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide ~ ~ N
-H
N -N N, N ~ O
S / N
O H
[210] EXAMPLE 24 was prepared according to the procedure described above for EXAMPLE 20 using 3-ainino-4-methyl-thiophene-2-carboxylic acid methyl ester instead of 3-amino-thiophene-2-carboxylic acid methyl ester. MS (ES+) 513 [M+1].
[211] EXAMPLE 25 3-[(Quinolin-4-ylmethyl) amino] -N-( l,1', 3-trimethyl-2'-oxo-1', 2'-dihydro spiro [imidazoli dine-2,3'-indol]-5'-yl)thiophene-2-carboxamide \\ N
N N N
N'0 j~N
O ~ \
] EXAMPLE 25 was prepared according to the procedure described for [212 EXAMPLE 15 using 5'-amino-l,3-dimethylspiro[imidazolidine-2,3'-indol]-2'(1'H)-one (compound 31 in the procedure below) instead of 5-amino-1'-methylspiro[indole-3,4'-piperidin]-2(lH)-one. MS (ES+) 513 [M+1].
O i. NaH THF O Nn 02N I~ O ii. Mel OzN I~ HZN -~ N
i H / N ~=O I/ N O
[213] Part 1:
[214] 1-Methyl-5-nitro-lH-indole-2,3-dione (31): To a suspension of 5-nitro-lH-indole-2,3-dione (7.69g, 40.0mmo1) in THF (100mL) was added NaH (60% in mineral oil, 2.40g, 60.0mmol). After stirring for lh at rt, MeI (3.74mL, 60.0mmo1) was added. The mixture was stirred at rt overnight, quenched with brine (8OmL), and extracted with dichloromethane (3 x 100mL). The organic extracts were combined, dried over MgSO4i filtered, and concentrated in vacuo. The crude solid was recrystallized from acetonitrile to yield methylated product 30. 1H NMR (CDCl3, 400MHz): S 3.07 (s, 3 H), 6.59 (d, J= 8.2 Hz, 1 H), 6.67 (dd, J= 2.4, 8.2 Hz, 1 H), 6.74 (d, J= 2.4 Hz, 1 H). MS (ES+):
m/z 207 [M+1]. This material was converted to 5'-amino-l,3-dimethylspiro[imidazolidine-2,3'-indol]-2'(l'F)-one (31) using the same procedure as in the synthesis of 1',2'-dihydrospiro[1,3-dioxolane-2,3'-indol]-5'-amine (29).
[215] EXAMPLE 26 4-Methyl-3 -[(quinolin-4-ylmethyl) amino] -N-(1,1', 3-trimethyl-2'-oxo- l', 2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)thiophene-2-carboxamide N N_ N (/ ~ O
S O N
[216] EXAMPLE 26 was prepared according to the procedure described above for EXAMPLE 25 using 3-amino-4-methyl-thiophene-2-carboxylic acid methyl ester instead of 3-amino-thiophene-2-carboxylic acid methyl ester. MS (ES+) 527 [M+1].
N S S
S N_~'\J~i!~O
O 1 ~ -38-[200] EXAMPLE 19 was prepared according to the procedure described for EXAMPLE 18 using ethylene thioglycol instead of ethylene glycol. MS (ES+) 505 [M+1].
[2011 EXAMPLE 20 N-(1,3-Dimethyl-2'-oxo-1',2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide / \ N
H
N N -N N~
C ~
O O
S 1 ~ H
[202] EXAMPLE 20 was prepared according to the procedure described for EXAMPLE 18 using N,N'-dimethylethylenediamine instead of ethylene glycol. MS
(ES+) 499 [M+1].
[203] EXAMPLE 21 N-(2'-Oxo-1',2'-dihydrospiro[ 1,3-dioxane-2,3'-indol]-5'-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide S / \ DN
_ H N ci300 H
[204] EXAMPLE 21 was prepared according to the procedure described for EXAMPLE 18 using propylene glycol instead of ethylene glycol. MS (ES+) 487 [M+1]
[205] EXAMPLE 22 4-Methyl-N-(2'-oxo-1', 2'-dihydro spiro [ 1, 3-dioxolane-2, 3'-indol] -5'-yl)-3 -[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide / \ N
N O O
N ~ O
S / N
O H
[206] EXAMPLE 22 was prepared according to the procedure described above for EXAMPLE 17 using 3-amino-4-methyl-thiophene-2-carboxylic acid methyl ester instead of 3-amino-thiophene-2-carboxylic acid methyl ester. MS (ES+)487 [M+1].
[207] EXAMPLE 23 4-Methyl-N-(2'-oxo-l',2'-dihydrospiro[1,3-dithiolane-2,3'-indol]-5'-yl) -3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide / \ N
H
N S S
N O
S N
O H
[208] EXAMPLE 23 was prepared according to the procedure described above for EXAMPLE 19 using 3-amino-4-methyl-thiophene-2-carboxylic acid methyl ester instead of 3-amino-thiophene-2-carboxylic acid methyl ester. MS (ES+)519 [M+1].
[209] EXAMPLE 24 N-(1,3-Dimethyl-2'-oxo-l',2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)-4-methyl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide ~ ~ N
-H
N -N N, N ~ O
S / N
O H
[210] EXAMPLE 24 was prepared according to the procedure described above for EXAMPLE 20 using 3-ainino-4-methyl-thiophene-2-carboxylic acid methyl ester instead of 3-amino-thiophene-2-carboxylic acid methyl ester. MS (ES+) 513 [M+1].
[211] EXAMPLE 25 3-[(Quinolin-4-ylmethyl) amino] -N-( l,1', 3-trimethyl-2'-oxo-1', 2'-dihydro spiro [imidazoli dine-2,3'-indol]-5'-yl)thiophene-2-carboxamide \\ N
N N N
N'0 j~N
O ~ \
] EXAMPLE 25 was prepared according to the procedure described for [212 EXAMPLE 15 using 5'-amino-l,3-dimethylspiro[imidazolidine-2,3'-indol]-2'(1'H)-one (compound 31 in the procedure below) instead of 5-amino-1'-methylspiro[indole-3,4'-piperidin]-2(lH)-one. MS (ES+) 513 [M+1].
O i. NaH THF O Nn 02N I~ O ii. Mel OzN I~ HZN -~ N
i H / N ~=O I/ N O
[213] Part 1:
[214] 1-Methyl-5-nitro-lH-indole-2,3-dione (31): To a suspension of 5-nitro-lH-indole-2,3-dione (7.69g, 40.0mmo1) in THF (100mL) was added NaH (60% in mineral oil, 2.40g, 60.0mmol). After stirring for lh at rt, MeI (3.74mL, 60.0mmo1) was added. The mixture was stirred at rt overnight, quenched with brine (8OmL), and extracted with dichloromethane (3 x 100mL). The organic extracts were combined, dried over MgSO4i filtered, and concentrated in vacuo. The crude solid was recrystallized from acetonitrile to yield methylated product 30. 1H NMR (CDCl3, 400MHz): S 3.07 (s, 3 H), 6.59 (d, J= 8.2 Hz, 1 H), 6.67 (dd, J= 2.4, 8.2 Hz, 1 H), 6.74 (d, J= 2.4 Hz, 1 H). MS (ES+):
m/z 207 [M+1]. This material was converted to 5'-amino-l,3-dimethylspiro[imidazolidine-2,3'-indol]-2'(l'F)-one (31) using the same procedure as in the synthesis of 1',2'-dihydrospiro[1,3-dioxolane-2,3'-indol]-5'-amine (29).
[215] EXAMPLE 26 4-Methyl-3 -[(quinolin-4-ylmethyl) amino] -N-(1,1', 3-trimethyl-2'-oxo- l', 2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)thiophene-2-carboxamide N N_ N (/ ~ O
S O N
[216] EXAMPLE 26 was prepared according to the procedure described above for EXAMPLE 25 using 3-amino-4-methyl-thiophene-2-carboxylic acid methyl ester instead of 3-amino-thiophene-2-carboxylic acid methyl ester. MS (ES+) 527 [M+1].
Claims (25)
- Claim 1. A compound represented by Formula (1):
or a pharmaceutically acceptable salt or N-oxide thereof, wherein:
Y is heteroaryl or cycloC3-10alkyl, either of which is optionally substituted by 1-5 independent R2 substituents;
X is heteroaryl or heterocylyl, either of which is optionally substituted by 1-independent R21 substituents;
A is aryl, heteroaryl, cycloC3-10alkyl, heterocyclyl, cycloC3-10alkenyl, or heterocycloalkenyl, each of which is optionally substituted by 1-5 independent substituents;
R1 is C0-6alkyl, halogen, or haloalkyl;
R2, R21, and R3 each independently is C0-6alkyl, cycloC3-10alkyl, oxo, halogen, haloalkyl, cyanoC0-6alkyl, nitroC0-6alkyl, hydroxyC0-6alkyl, -C0-6alkyl N(C0-6alkyl)(C0-6alkyl), -N(C0-6alkyl)-N(C0-6alkyl)(C0-6alkyl), -N(C0-6alkyl)-N(C0-6alkyl)(acyl), acylC0-6alkyl, substituted acyl, guanidinoC0-6alkyl, hydroxyiminoC0-6alkyl, acylaminoC0-6alkyl, substituted acylamino, acyloxyC0-6alkyl, substituted acyloxy, arC0-6alkyl, substituted arC0-6alkyl, heteroarylC0-6alkyl, substituted heteroarylC0-6alkyl, heterocyclylC0-6alkyl, cyanoaminoC0-6alkyl, C0-6alkylhydrazino, heterocyclylamino, arC0-6alkylhydrazino, alkylsulfonylC0-6alkyl, arC0-6alkylsulfonylC0-6alkyl, alkylsulfinylC0-6alkyl, alkylsulfonamidoC0-6alkyl, arC0-6alkylsulfonamidoC0-6alkyl, aminoC0-6alkylsulfonyl, C0-6alkylaminosulfonyl, acylC1-6alkylsulfonyl, heterocyclylsulfonyl, aminoC0-6alkylsulfinyl, acylC1-6alkylsulfinyl, silyl, siloxy, alkenoxy, alkynoxy, C2-6alkenyl, acylC2-6alkenyl, C2-6alkynyl, acylC2-6alkynyl, hydroxyC2-6alkynyl, aminoC2-6alkynyl, C1-6alkoxyC0-6alkyl, C1-6alkylthioC0-6alkyl, hydroxyC1-6alkoxyC0-6alkyl, hydroxyC1-6alkylthioC0-6alkyl, acylC1-6alkoxyC0-6alkyl, acylC1-6alkylthioC0-6alkyl, C0-6alkylaminoC1-6alkoxyC0-6alkyl, C0-6alkylaminoC1-6alkylthioC0-6alkyl, acylaminoC1-6alkoxyC0-6alkyl, acylaminoC1-6alkylthioC0-6alkyl, arC0-6alkylaminoC0-6alkyl, arC0-6alkylthioC0-6alkyl, arC0-6alkoxyC0-6alkyl, arC0-6alkylamino, arC0-6alkylaminoC0-6alkyl, arC0-6alkylthio, substituted arC0-6alkoxy, substituted arC0-6alkylthio,or substituted arC0-6alkoxy;
and provided that the compound is not cis-N-(4-methyl-5-oxo-1,4-diazaspiro[5.5]undec-9-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide, cis-N-(2-benzyl-3 -oxo-1,2-diazaspiro[4.5]dec-8-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide, N-(3-benzyl-2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide, cis-N-(2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide, N-[3-(3-methylbutyl)-2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl]-4-methyl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide, or benzyl 5-{[(3-[(quinolin-4-ylmethyl)amino]thien-2-yl)carbonyl]amino}-2-oxo-1,2-dihydro-1'H-spiro[indole-3,4'-piperidine]-1'-carboxylate. - Claim 2 The compound according to claim 1 wherein Y is cycloC3-10alkyl optionally substituted by 1-5 independent R2 substituents; and X is heterocyclyl or heteroaryl, optionally substituted by 1-5 independent R21 substituents.
- Claim 3. The compound according to any of claims 1 or 2 wherein Y is cyclohexyl optionally substituted by 1-5 independent R2 substituents.
- Claim 4. The compound according to any of claims 1-3 wherein A is heteroaryl.
- Claim 5. The compound according to any of claims 1-4 wherein A is
- Claim 6. The compound according to any of claims 1-5 wherein R1 is C0-6alkyl.
- Claim 7. The compound according to any of claims 1, 2, 4-6 wherein Y is heteroaryl optionally substituted by 1-5 independent R2 substituents; and X is heterocyclyl optionally substituted by 1-5 independent R21 substituents.
- Claim 8. The compound according to any of claims 1, 2, 4-6 wherein Y is cycloC3-10alkyl optionally substituted by 1-5 independent R2 substituents; and X is heterocyclyl optionally substituted by 1-5 independent R21 substituents.
- Claim 9. The compound according to claim 7 wherein A is heteroaryl.
- Claim 10. The compound according to claim 9 wherein A is
- Claim 11. The compound according to claim 10 wherein R1 is C0-6alkyl.
- Claim 12. A composition comprising a compound according to any of claims 1-12, or a pharmaceutically acceptable salt or N-oxide thereof; and a pharmaceutically acceptable carrier.
- Claim 13. A composition comprising a compound according to any of claims 1-12, or a pharmaceutically acceptable salt or N-oxide thereof; and an anti-neoplastic, anti-tumor, anti-angiogenic, or chemotherapeutic agent.
- Claim 14. A composition comprising a compound according to any of claims 1-12, or a pharmaceutically acceptable salt or N-oxide thereof; and a cytotoxic cancer therapeutic agent.
- Claim 15. A composition comprising a compound according to any of claims 1-12, or a pharmaceutically acceptable salt or N-oxide thereof; and an angiogenesis inhibiting cancer therapeutic agent.
- Claim 16. A compound consisting of N-1,4-dioxaspiro[4 5]dec-8-yl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
cis-N-1-oxa-4-thiaspiro[4.5]dec-8-yl-3-[(quinolin-4-ylmethyl)ammo]thiophene-2-carboxamide;
trans-N-1-oxa-4-thiaspiro[4.5]dec-8-yl-3-[(quinolin-4-ylmethyl)amino]thiophene-carboxamide;
N-(2-methyl-3-oxo-1,2-diazaspiro[4.5]dec-8-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
trans-N-(2-benzyl-3-oxo-1,2-diazaspiro[4.5]dec-8 -yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
cis-N-(1,4-dimethyl-5-oxo-1,4-diazaspiro[5.5]undec-9-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
trans-N-(1,4-dimethyl-5-oxo-1,4-diazaspiro[5.5]undec-9-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
cis-N-(3'-oxo-3',4'-dihydro-1'H-spiro[cyclohexane-1,2'-quinoxalin]-4-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
trans-N-(3'-oxo-3',4'-dihydro-1'H-spiro[cyclohexane-1,2'-quinoxalin]-4-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(3-oxo-2-azaspiro[4.5]dec-8-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-1,4-dioxaspiro[4.5]dec-8-yl-4-methyl-3-[(quinolin-4-ylmethyl)amino]thiophene-carboxamide;
trans-N-(2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(3-methyl-2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-[3-(3-methylbutyl)-2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl]-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(1'-methyl-2-oxo-1,2-dihydrospiro[indole-3,4'-piperidin]-5-y1)-3-[(quinolin-ylmethyl)amino]thiophene-2-carboxamide;
N-(2'-oxo-1',2'-dihydrospiro[1,3-dioxolane-2,3'-indol]-5'-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-1',2'-dihydrospiro[1,3-dioxolane-2,3'-indol]-5'-yl-3-[(pyridin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(2-oxo-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-pyran]-5-yl)-3-[(quinolin-ylmethyl)amino]thiophene-2-carboxamide;
N-(2'-oxo-1',2'-dihydrospiro[1,3-dithiolane-2,3'-indol]-5'-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(1,3-dimethyl-2'-oxo-1',2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
3-[(quinolin-4-ylmethyl)ammo]-N-(1,1',3-trimethyl-2'-oxo-1',2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)thiophene-2-carboxamide;
N-(2'-oxo-1',2'-dihydrospiro[1,3-dioxane-2,3'-indol]-5'-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
4-methyl-N-(2'-oxo-1',2'-dihydrospiro[1,3-dioxolane-2,3'-indol]-5'-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
4-methyl-N-(2'-oxo-1',2'-dihydrospiro[1,3-dithiolane-2,3'-indol]-5'-yl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
N-(1,3-dimethyl-2'-oxo-1',2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)-4-methyl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
4-methyl-3-[(quinolin-4-ylmethyl)ammo]-N-(1,1',3-trimethyl-2'-oxo-1',2'-dihydrospiro[imidazolidine-2,3'-indol]-5'-yl)thiophene-2-carboxamide; or a pharmaceutically acceptable salt, or N-oxide, thereof. - Claim 17. A compound consisting of or a pharmaceutically acceptable salt, or N-oxide, thereof.
- Claim 18. A compound consisting of or a pharmaceutically acceptable salt, or N-oxide, thereof.
- Claim 19. A method of treatment of hyperproliferative disorder comprising a step of administering an effective amount of the compound according to any of claims 1-11, or 16-18.
- Claim 20. The method of claim 19, further comprising the step of administering an anti-neoplastic, anti-tumor, anti-angiogenic, or chemotherapeutic agent.
- Claim 21. The method of claim 19 wherein the hyperproliferative disorder is breast cancer, head cancer, or neck cancer.
- Claim 22. The method of claim 19 wherein the hyperproliferative disorder is gastrointestinal cancer.
- Claim 23. The method of claim 19 wherein the hyperproliferative disorder is leukemia.
- Claim 24 The method of claim 19 wherein the hyperproliferative disorder is ovarian, bronchial, lung, or pancreatic cancer.
- Claim 25. The method of claim 19 wherein the hyperproliferative disorder is mastocytosis/mast cell leukemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61067204P | 2004-09-17 | 2004-09-17 | |
US60/610,672 | 2004-09-17 | ||
PCT/US2005/033127 WO2006034015A1 (en) | 2004-09-17 | 2005-09-15 | (spirocyclylamido) aminothiophene compounds as c-kit proto- oncogene inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2581150A1 true CA2581150A1 (en) | 2006-03-30 |
Family
ID=35586683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002581150A Abandoned CA2581150A1 (en) | 2004-09-17 | 2005-09-15 | (spirocyclylamido) aminothiophene compounds as c-kit proto- oncogene inhibitors |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060063791A1 (en) |
EP (1) | EP1817310A1 (en) |
JP (1) | JP2008513476A (en) |
CN (1) | CN101061112A (en) |
AR (1) | AR051372A1 (en) |
AU (1) | AU2005287057A1 (en) |
CA (1) | CA2581150A1 (en) |
TW (1) | TW200621758A (en) |
WO (2) | WO2006034110A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0306309A (en) | 2002-09-09 | 2004-10-19 | Janssen Pharmaceutica Nv | Hydroxyalkyl substituted 1,3,8-triazaospiro [4.5] decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders |
JP2008542375A (en) * | 2005-06-02 | 2008-11-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators |
US20080051585A1 (en) * | 2006-08-17 | 2008-02-28 | Wyeth | Process for the preparation of indolin-2-one derivatives useful as PR modulators |
EP1921070A1 (en) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation |
JP5377332B2 (en) | 2007-02-06 | 2013-12-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bicyclic heterocycles, drugs containing these compounds, their use and their preparation |
CN101679430B (en) | 2007-04-09 | 2013-12-25 | 詹森药业有限公司 | 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of ORL-i receptor for treatment of anxiety and depression |
CA2711582A1 (en) | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles, formulations containing said compounds, use thereof and processes for the preparation thereof |
JP5539351B2 (en) | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cyclohexyloxy-substituted heterocycles, medicaments containing these compounds, and methods for producing them |
SG192216A1 (en) | 2011-02-01 | 2013-09-30 | Boehringer Ingelheim Int | 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof |
GB201113430D0 (en) | 2011-08-03 | 2011-09-21 | Fermentas Uab | DNA polymerases |
WO2014012859A1 (en) | 2012-07-19 | 2014-01-23 | Boehringer Ingelheim International Gmbh | Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof |
EP2881391A1 (en) | 2013-12-05 | 2015-06-10 | Bayer Pharma Aktiengesellschaft | Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof |
BR112017000762A2 (en) | 2014-07-15 | 2017-11-21 | Gruenenthal Gmbh | azaspiro derivatives (4.5) substituted dean. |
TW201607923A (en) | 2014-07-15 | 2016-03-01 | 歌林達有限公司 | Substituted azaspiro (4.5) decane derivatives |
WO2018078009A1 (en) * | 2016-10-29 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives |
EP3679043B9 (en) * | 2017-09-05 | 2023-09-27 | Neumora Therapeutics, Inc. | Vasopressin receptor antagonists and products and methods related thereto |
KR102267662B1 (en) * | 2019-11-19 | 2021-06-22 | 한국화학연구원 | Benzamide derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9717576D0 (en) * | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
TWI299664B (en) * | 2003-01-06 | 2008-08-11 | Osi Pharm Inc | (2-carboxamido)(3-amino)thiophene compounds |
US7388012B2 (en) * | 2004-09-17 | 2008-06-17 | Osi Pharmaceuticals, Inc. | (Hydrazido)(amino)thiophene compounds |
-
2005
- 2005-09-15 JP JP2007532491A patent/JP2008513476A/en active Pending
- 2005-09-15 CN CNA2005800393847A patent/CN101061112A/en active Pending
- 2005-09-15 US US11/227,345 patent/US20060063791A1/en not_active Abandoned
- 2005-09-15 WO PCT/US2005/033318 patent/WO2006034110A1/en active Application Filing
- 2005-09-15 CA CA002581150A patent/CA2581150A1/en not_active Abandoned
- 2005-09-15 WO PCT/US2005/033127 patent/WO2006034015A1/en active Application Filing
- 2005-09-15 EP EP05812739A patent/EP1817310A1/en not_active Withdrawn
- 2005-09-15 AU AU2005287057A patent/AU2005287057A1/en not_active Abandoned
- 2005-09-16 TW TW094132237A patent/TW200621758A/en unknown
- 2005-09-20 AR ARP050103918A patent/AR051372A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR051372A1 (en) | 2007-01-10 |
WO2006034110A1 (en) | 2006-03-30 |
WO2006034015A1 (en) | 2006-03-30 |
TW200621758A (en) | 2006-07-01 |
AU2005287057A1 (en) | 2006-03-30 |
EP1817310A1 (en) | 2007-08-15 |
JP2008513476A (en) | 2008-05-01 |
US20060063791A1 (en) | 2006-03-23 |
CN101061112A (en) | 2007-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2581150A1 (en) | (spirocyclylamido) aminothiophene compounds as c-kit proto- oncogene inhibitors | |
US20200085821A1 (en) | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | |
AU2009215534B2 (en) | Compounds that are ERK inhibitors | |
JP7029388B2 (en) | Isoindolein inhibitor of MDM2-P53 interaction with anti-cancer activity | |
JP2022524759A (en) | Carboxamide-pyrimidine derivative as an SHP2 antagonist | |
WO2017009798A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
CA3030795A1 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
TWI481601B (en) | Nitrogen-containing compound and pharmaceutical composition | |
MX2010008926A (en) | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases. | |
CA2698071A1 (en) | Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system | |
AU2006326616A1 (en) | Polycyclic indazole derivatives that are ERK inhibitors | |
CN113329791A (en) | 9-substituted amino-triazoloquinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and uses thereof | |
TW202137979A (en) | Anti-tumor effect potentiator using novel biphenyl compound | |
CA2723279A1 (en) | 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses | |
JP2018515466A (en) | Polycyclic indoline compounds and indolenine compounds | |
US7439256B2 (en) | (Arylamidoaryl) cyanoguanidine compounds | |
US7388012B2 (en) | (Hydrazido)(amino)thiophene compounds | |
US7829717B2 (en) | (Arylamidoaryl)squaramide compounds | |
JP2009523799A (en) | Piperazine derivatives as farnesyl protein transferase inhibitors | |
US7618965B2 (en) | (Arylamidoanilino)nitroethylene compounds | |
KR20240130085A (en) | Tricyclic derivative inhibitors, methods for preparing the same and applications thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |